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ABSTRACT 
IN VIVO FAST SCAN CYCLIC VOLTAMMETRY REVEALS DISTINCT DOMAINS OF 
DOPAMINE TERMINAL FUNCTION IN THE STRIATUM 
 
Keith F. Moquin Ph.D. 
 
University of Pittsburgh, 2011 
 
 
The striatal dopaminergic system regulates several brain functions; movement, cognition, 
motivation, and reward. As such, failures of this system lead to numerous diseases including 
Parkinson’s disease, schizophrenia, and drug addiction. Dopaminergic neurons communicate 
with, and regulate the function of, target cells by controlling the extracellular dopamine 
concentration. Release of dopamine from neuron terminals elevates the extracellular 
concentration activating pre- and post-synaptic transmembrane receptor proteins. Clearance of 
dopamine via the dopamine transporter lowers the extracellular concentration, terminating 
dopamine receptor activation. This dissertation focuses on the role the pre-synaptic dopamine 
D2-receptor and the dopamine transporter play in the management of extracellular dopamine 
concentrations, i.e. dopamine signaling. 
We employ carbon fiber electrodes in conjunction with fast scan cyclic voltammetry to 
detect changes in the extracellular dopamine concentration during and after electrical stimulation 
of dopamine neurons. Fast scan cyclic voltammetry is the ideal analytical method to detect 
dopamine signaling events because it has a high spatiotemporal resolution that can track sub-
second changes in the extracellular dopamine concentration from small populations of terminals. 
Pharmacological drugs are used to determine the role of D2-receptor and dopamine transporter 
proteins in controlling the extracellular dopamine concentration. 
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Our results reveal that differences in dopamine transporter function alter D2-receptor 
activation, segmenting the striatum into two domains of dopamine terminals; fast and slow. 
Localized fast domains, which fit the classic model, release dopamine immediately upon 
stimulation and clear dopamine rapidly following the stimulus. In Slow domains, evoked release 
is initially inhibited but accelerates as stimulation continues. The rate of dopamine clearance 
from slow domains is significantly slower. Thus, we redefine the striatal dopamine system, once 
thought to be homogenous, as a pathway comprised of two distinct domains of dopamine 
function. These results reveal a previously undiscovered slow domain of dopaminergic activity; 
changing our understanding of how the striatal dopaminergic system regulations brain function, 
and providing new insights into the causes of, and therapies for, dopaminergic pathologies. 
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1.0 INTRODUCTION 
 
1.1 ABSTRACT 
 
The first time I hiked in a forest my dad stressed to me the importance of looking back the way 
you came. When I asked him why, he replied: “because the path you take often looks very 
different when viewed from the other direction. If you aren’t familiar with the surroundings you 
can get lost”. Looking back not only reveals where you have been, but it also provides the 
context for where you are and enlightens the path forward. Without this knowledge we are 
doomed to wander aimlessly amongst the trees.  
This dissertation focuses on the mechanisms controlling the release and clearance of the 
neurotransmitter dopamine from the extracellular space. The rates of dopamine release and 
clearance determine the extracellular dopamine concentration, and thus the time course of 
neurotransmitter signaling. The following chapter provides an overview of the in vivo detection 
of dopamine neuron activity. Basic striatal dopaminergic neuron anatomy and function is 
explained. The advantages and limitations of the electrochemical method fast scan cyclic 
voltammetry in the detection of dopamine are discussed. Finally, the current model of striatal 
dopamine signaling is presented. Successes and knowledge gaps are highlighted, providing an 
orientation for this dissertation and the backdrop for its significance in the field. 
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1.2 THE NIGROSTRIATAL DOPAMINERGIC SYSTEM 
 
The nigrostriatal dopamine pathway is one of four main dopamine pathways in the brain. 
Dopamine neurons originate in the substantia nigra. Each neuron extends an axon from the 
substantia nigra, through the medial forebrain bundle, into the striatum (Carr and White 1986; 
Horvitz 2000). There, they branch into millions of DA terminals that innervate the entire striatum 
with a 2 µm average distance of separation (Doucet et al 1988). Each DA terminal forms a 
synapse with a gamma-aminobutyric acid (GABA) neuron dendrite or spine, forming a synaptic 
junction. The two cell walls do not touch, leaving a 15 nm thick and 300 nm wide synaptic gap 
between the two cell walls (Garris et al 1994). The synaptic gap empties into a larger 
extracellular space, which comprises 20% of the striatum’s total volume (Cserr et al 1991; 
Nicholson and Rice 1991; Cragg et al 2001). Cerebral spinal fluid, a buffer solution, fills the 
synaptic gap and the extracellular space, allowing small molecules: ions, neurotransmitters, 
oxygen, etc., to move freely between cells.  
It is in this buffer solution that DA terminals convey their message to the GABA neuron 
cell body. This message is a vital component in the regulation of several functions including 
motion, cognition, motivation, and reward. A dysfunctional nigrostriatal dopamine pathway is 
linked to several disorders such as Parkinson’s disease, attention deficit hyperactivity disorder, 
schizophrenia, and drug addiction (Grace 1991; Abi-Dargham et al 2000; Swanson et al 2000; 
Lotharius and Brundin 2002; Phillips et al 2003b; Salahpour et al 2008). It is necessary to learn 
how DA neurons communicate information in order to understand how the DA system regulates 
function and causes DA based disorders.  
Because the GABA cell and DA terminal do not form a direct connection, they 
communicate via the interaction of the neurotransmitter dopamine with target receptor proteins. 
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This protein is a transmembrane g-protein coupled receptor that spans the cell wall (Clark and 
White 1987). The protein has two main components; the DA binding site in the extracellular 
space and a g-protein binding site in the intracellular space. DA binding to the receptor protein 
causes a conformational change to occur, altering the binding affinity of the receptor to the g-
protein. The activated g-protein interacts with the adenylate cyclase enzyme, altering cyclic 
AMP production (Monsma et al 1990; Schinelli et al 2004). There are two types of DA receptor 
proteins; D1-like receptors that increase cyclic AMP production, and D2-like receptors that 
inhibit cyclic AMP production. GABA cells contain both D1- and D2-like receptors, DA 
terminals only have D2-receptors (D2R) (Delle-Donne et al 1997).  
The DA binding constant to DA receptor proteins is 1-2 µM (Grigoriadis and Seeman 
1985). Below this concentration threshold the GABA receptor cell does not receive a DA signal 
input. DA terminals regulate the extracellular DA concentration, controlling the time course of 
DA signaling at the GABA cell. DA terminals adjust the DA extracellular concentration by 
regulating the rate of DA release from, and clearance into, the terminal. The balance of release 
and clearance set the extracellular DA concentration, and thus the time course of DA signaling.  
In the terminal, DA is contained in spherical lipid bilayers called vesicles (Greengard et 
al 1993; Sulzer et al 1995). A high frequency train of action potentials lasting several hundred 
milliseconds are sent from the cell body through the axon to the terminal. Here they open 
calcium ion channels, increasing the intracellular Ca2+ concentration. The influx of calcium 
causes vesicle fusion to the terminal cell wall, releasing dopamine into the synaptic gap. DA 
diffuses throughout the extracellular space binding to DA receptors, i.e. signaling. DA binding to 
the pre-synaptic D2R triggers an autoinhibitory effect, suppressing further DA release 
(Limberger et al 1991; Benoit-Marand et al 2001). 
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It is important to note that several lines of evidence suggest that DA signaling occurs in 
the extracellular space, not the synaptic gap. In the striatum, DA diffuses at a rate of 2.4x10-6 
cm2/s (Rice et al 1985; Nicholson and Rice 1991; Nicholson 1995). At this rate, DA diffuses out 
of the synaptic gap into the extracellular space (area: 4.5x10-11 cm2) in approximately 2.0x10-5 s 
(Garris et al 1994). Also, DA receptors are located in the extracellular space, not the synaptic 
gap (Sesack et al 1994). Therefore it is the concentration of DA in the extracellular space that 
determines DA signaling events.  
In order to terminate a signal, DA is cleared from the extracellular space back into the 
terminal by a transporter protein located only on the terminals (Ciliax et al 1995; Nirenberg et al 
1996). The DA transporter (DAT) is a symporter that couples DA movement with the influx of 
two sodium ions (Torres et al 2003). DAT clears DA from the extracellular space quickly, with 
some studies reporting a DA clearance rate of 5 µM/s (Wu et al 2002). This rapid uptake process 
limits DA’s distance of diffusion in the striatum to tens of microns (Garris et al 1994; Cragg and 
Rice 2004). Also, the DAT can transport DA from the cytoplasm into the extracellular space, a 
process called reverse transport (Sulzer et al 1995).  
DA release, clearance, autoinhibition, diffusion, and reverse transport all contribute to the 
steady state extracellular DA concentration as well as the magnitude and duration of DA release 
events. Because these processes are rapid, monitoring DA signaling requires an analytical 
method that is selective to DA, has a high nM detection limit, and a subsecond temporal 
resolution. Further, this device must be small enough to minimize tissue damage during in vivo 
sampling (Rousche and Normann 1998; Szarowski et al 2003; Biran et al 2005; Jaquins-Gerstl 
and Michael 2009).  
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1.3 IN VIVO ELECTROCHEMISTRY AND DOPAMINE 
 
In the spring of 1973, the first paper utilizing electrochemical analytical techniques to monitor 
changes in the concentration of the small neurotransmitter, dopamine, in living tissue was 
published in the journal of Brain Research (Kissinger et al 1973). This article marks the first 
time neurological events were monitored as they occurred in real time in a living system. Today, 
that publication has spawned an entire field of research, significantly increasing our 
understanding of neurological function. The following section explains the in vivo technique and 
its advantages and limitations in the detection of DA, while providing a brief history of early in 
vivo electrochemistry.   
Electrochemistry applies voltage potentials to an electrode surface, a carbon fiber 
electrode (CFE) in this case, to drive oxidation and reduction processes, and then measures the 
current generated from these reactions.  The potential required to run these redox reactions is 
analyte specific, and the magnitude of the generated current is proportional to the analyte 
concentration. Thus, electrochemistry can be used to identify and quantify electroactive species 
in a sample.  
 Typically, the applied voltages needed to complete the oxidation and reduction cycle are 
separated by  59 𝑚𝑉
𝑛
 , where n is the number of electrons (Bard and Faulkner 2001). In order to 
detect both oxidation and reduction, cyclic voltammetry is performed. First, the applied potential 
is ramped at a constant rate from a rest potential to a potential greater than the oxidation 
potential, oxidizing the species. The scan is then reversed back to the rest potential, reducing the 
species. Typical cyclic voltammetry scan rates range from 1 mV/s to 1 V/s. A cyclic 
voltammogram plots the current change versus potential revealing the peak oxidation and 
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reduction potentials. The locations of these peaks are specific to the species and the experimental 
conditions. Thus the cyclic voltammogram acts as an analyte fingerprint.  
DA is an electroactive catecholamine with two hydroxyl groups attached to the 3rd and 4th 
position of the benzene ring. The catechol group can be oxidized, removing two electrons and 
two protons, converting dopamine into dopamine-o-quinone (DAQ). This process is reversible, 
so DAQ can be reduced back to DA with the addition of two electrons and two protons.  
DA, however, does not go through a typical redox reaction. The removal (oxidation) and 
addition (reduction) of the two electrons and two protons on each DA molecule occur as four 
separate events, not as one reaction (Deakin et al 1986; Wipf et al 1986). As such, there are six 
possible pathways for DA oxidation and DAQ reduction, known as the nine-member box 
(Larivon 1984). DA oxidation and DAQ reduction do not follow the same pathway, so the 
separation of oxidation and reduction potentials is larger than 29.5 mV. Even at 1 V/s, the time 
delay between scanning the oxidization and reduction potentials allows DAQ produced by DA 
oxidation to diffuse away from the microelectrode surface.  The resulting cyclic voltammogram 
has a sigmoidal shape without a discernable reduction peak (Bard and Faulkner 2001).  
In order to detect the reduction peak, and thus accurately identify DA, fast scan cyclic 
voltammetry (FSCV) is employed. FSCV is cyclic voltammetry at fast scan rates (400 V/s in our 
hands). At this scan rate, DA oxidizes at 650 mV and DAQ reduces at -250 mV (all potentials vs 
a Ag/AgCl reference electrode). Fast scan rates have two added bonuses in the in vivo detection 
of DA. First, at a sweep rate of 400 V/s, the 3 V scan takes 7.5 ms to complete. Therefore, DA 
scans can be repeated at 10 Hz, giving FSCV sub-second temporal resolution (Bath et al 2000; 
Robinson et al 2001). Second, the fast scan rate eliminates any interference from ascorbic acid, 
an anti-oxidant found in the brain at 200-400 µM concentrations (Gonon et al 1981). Ascorbic 
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acid has similar oxidation and reduction peaks, but the electrochemical redox reactions are 
slower than DA. At fast scan rates, the ascorbic acid redox reactions do not occur, and therefore 
do not contribute to the detected change in current. Another way to eliminate ascorbic acid 
signals is to coat the electrode surface with a Nafion polymer layer, which prevents anions, e.g. 
ascorbic acid, from reaching the electrode surface (Gerhardt et al 1984). However, this layer 
slows DA’s migration to the electrode, creating a diffusional distortion that must be 
deconvoluted (Kawagoe et al 1992; Garris et al 1994; Garris and Wightman 1995). 
The CFE used to detect DA has a diameter of 7 µm and can be cut to any length ranging 
from 1 mm to a disk. The electrode’s size limits brain damage caused during implantation, 
enabling the electrode to monitor DAergic events from minimally altered neurons (Clapp-Lilly et 
al 1999; Peters et al 2004; Jaquins-Gerstl and Michael 2009). Also, the electrode’s small surface 
area limits the number of terminals the electrode samples from. Thus, CFEs measure DA events 
from discrete terminal populations. Finally, the CFE is sensitive to changes in DA concentration 
and has a detection limit in the high nM range (Wightman et al 1978; Gonon et al 1984). Taken 
together, FSCV with a CFE is capable of detecting sub-second, high nM changes in DA 
concentration from small populations of neurons in vivo.  
FSCV has one major limitation. The technique is not well-suited to measuring the 
baseline analyte concentration. Each FSCV scan generates a large current 2000-2500 nA in 
amplitude over the entire potential scan. The main source of this signal comes from the non-
faradaic charging current caused by the fast scan rate. However, any faradaic current caused by 
oxidation and reduction reactions contributes as well. For example, high nM DA concentrations 
generate 1 -100 nA of current during a scan, representing less than 1 % of the total current. 
Further, the background current amplitude is unique to each experimental setup, electrode and 
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buffer solution. Therefore, it is impossible to detect or measure DA from a single fast scan cyclic 
voltammogram. (It is important to note that cyclic voltammetry does not have this issue. The 
slower scan rate produces a minimal non-faradaic current, enabling the detection of the faradaic 
current without interference.)  
Because of the large non-faradaic current, FSCV is best-suited to measuring changes in 
the DA concentration, not absolute values. In order to measure DA, at least two voltammetric 
scans are required; a background scan before a DA concentration change and a scan following 
the concentration change. The current generated from the non-faradaic source and faradaic 
current generated from electroactive species at a constant concentration remains unchanged in 
both scans. Subtracting the two cyclic voltammograms leaves only the current change due to the 
change in DA concentration. This process is repeated for each cyclic voltammogram recorded 
during the experiment. Plotting the current change from background at the DA oxidation 
potential (~650 mV) at the time point of each scan reveals changes in DA concentration over 
time.  
Cyclic voltammograms collected before the DA event have a similar current profile 
compared to the background voltammogram. Background Subtraction of these voltammograms 
yields a value of zero plus or minus noise. However, FSCV is a differential method, so the zero 
value represents the change in DA concentration, not the absolute value. In fact, the magnitude 
of change is independent of the baseline, or basal, DA concentration within the limits of 
detection. In other words, the signal generated by a 2 µM increase in the DA concentration will 
be identical in either a 1 nM or 1 µM basal DA concentration. For this reason FSCV is unable to 
measure the absolute concentration of DA. Despite this limitation, FSCV has proved a very 
powerful tool in the in vivo detection of DA signaling.  
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1.4 EVOKED DOPAMINE HETERGENEITY: THE FORK IN THE ROAD 
 
One way to create a detectable change in the extracellular DA concentration is to evoke DA 
release by electrical stimulation. In order to stimulate the neurons a bipolar stimulating electrode 
is placed on the medial forebrain bundle, which contains DAergic nerve axons, and an 
alternating electrical current is applied (Ewing et al 1983; Kuhr et al 1984; Heien et al 2005).  
The applied current depolarizes axons, sending an action potential to the terminal. The 
frequency, amplitude, and duration of the electrical stimulation are all factors in the amount of 
DA released by the stimulation (Wightman et al 1988; May and Wightman 1989a; Kawagoe et 
al 1992; Wu et al 2002).  
 However, stimulus parameters do not appear to be the sole determinant of the evoked DA 
profile and amplitude detected by the CFE. Initial studies discovered that the electrode 
stimulation evokes a range of detected DA release profiles (May and Wightman 1989b; 
Kawagoe et al 1992). These disparate responses are accessed by moving the CFE into a new 
striatal location (Kawagoe et al 1992; Wightman et al 2007). Early papers published on this 
evoked DA heterogeneity hypothesized that diffusion was the main source of the differences in 
the rate of evoked DA release (May and Wightman 1989b). The theory states that a slow initial 
response was the result of a CFE placed some distance from DA terminals. During an electrical 
stimulation, DA is immediately released by terminals, but  must diffuse to the electrode for 
detection causing a signal delay (Kawagoe et al 1992; Venton et al 2003). This hypothesis 
implies that these slow responses are caused by experimental error and are wrong. In order to 
correct for this error, the electrode location is optimized until the electrode detects an immediate 
evoked DA response. This fast response indicates that the CFE is immediately adjacent to the 
DA terminals (Venton et al 2003).  
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Despite the fact that the hypothesis was never proven, electrode optimization to find fast-
type responses has become ubiquitous in striatal DA experiments (Cass and Gerhardt 1994; 
Garris et al 1994; Benoit-Marand et al 2001; Robinson et al 2001; Venton et al 2002; 
Avshalumov and Rice 2003; Garris et al 2003; Phillips et al 2003a; Phillips et al 2003b; 
Robinson et al 2003; Cheer et al 2005; Heien et al 2005; Kita et al 2007; Wightman et al 2007; 
Sombers et al 2009; Addy et al 2010; Herr et al 2010). The electrode is placed in the striatum 
and the evoked response is recorded. If the response is not rapid, 1 µM in 0.2 s, the electrode is 
dialed lower into the striatum and the stimulus is repeated (May and Wightman 1989a). This 
entire process continues until the desired fast-type evoked DA response is detected. At this point 
the experiment starts. This method removes slow-type responses from the experiment, and thus 
from the literature.   
Due to electrode optimization, the past twenty five years of Striatal DA research in 
anesthetized and awake animals as well as in vitro tissue slices has focused almost exclusively 
on fast-type responses (Cragg et al 2001; Avshalumov and Rice 2003; Phillips et al 2003b; 
Cheer et al 2004; Heien et al 2005). The effects of DA receptor agonists and antagonists, and 
DAT inhibitors on both the basal DA concentration and profile of fast-type evoked DA has been 
thoroughly characterized (Sulzer et al 1995; Benoit-Marand et al 2001; Rougé-Pont et al 2002; 
Wu et al 2002; Greco and Garris 2003; Sevak et al 2007; Espana et al 2008). From these data a 
sophisticated model of DA neuron communication in the striatum has been formed.  
Transient DA release events occur at 1 Hz intervals releasing high nM concentrations 
into the extracellular space (Wightman and Robinson 2002; Heien et al 2005). A rapid DAT 
mediated DA uptake process quickly clears this DA, maintaining a 2-10 nM basal DA 
concentration (Wightman et al 2007). DA receptor binding is minimal at low nM concentrations, 
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so there is limited DA signaling and no pre-synaptic autoinhibition of release (Grigoriadis and 
Seeman 1985). The DA terminals are primed and ready to fire.  
Phasic action potentials sent to the terminals triggers vesicle fusion to the cell wall, 
releasing large concentrations of DA into the extracellular space. During this event the rate of 
vesicular release overwhelms the rate of DA uptake via DAT (Wightman et al 1988; Wu et al 
2001). The result is a 1-2 µM increase in the DA concentration recorded by the CFE within 0.2 s 
of the onset of the action potential (Benoit-Marand et al 2001; Wu et al 2001; Robinson et al 
2003). At this concentration, DA interacts with post-synaptic DA receptors on the GABA cell, 
i.e. DA signaling. The pre-synaptic D2R is also activated by this initial release process, 
triggering D2R mediated autoinhibition (Usiello et al 2000; Benoit-Marand et al 2001; Kita et al 
2007). This autoinhibitory effect suppresses further DA release in the face of continued 
stimulation. At the end of the stimulus, DA release stops and extracellular DA is cleared from the 
extracellular space back into the terminal by DAT within a second (Wu et al 2001; Wu et al 
2002). The extracellular concentration returns to the pre-stimulus 2-10 nM basal concentration. 
DA receptors are no longer bound by DA, so the neurological signal to the GABA cells and the 
autoinhibitory tone on the DA terminals is terminated.  
In this model DA signaling is limited by two factors. First, the low nM basal DA 
concentration limits DA signaling to phasic release events. In between these phasic events the 
basal concentration is below DA receptor activation (Grigoriadis and Seeman 1985). Second, 
rapid DA clearance and D2R mediated autoinhibition limits the duration of phasic events. Thus, 
this model suggests that DA signaling in the striatum only occurs for brief periods of time during 
phasic events. The majority of the time DA terminals are not signaling.  
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While accurate, the ‘fast-type’ model cannot be used to explain every DA based disorder. 
There are several paradoxes suggesting that phasic signaling is not the sole component of the 
striatal DA system. For example, attention deficit hyperactivity disorder (ADHD) is 
characterized by attention problems and hyperactivity. Theories suggest that increased DA 
signaling is the root cause of this disorder. In the ‘fast-type’ model increased DA signaling could 
be cause by an increase in the basal DA concentration, or an increase in the amplitude and 
duration of phasic release. ADHD is successfully treated with the DAT inhibitor, 
methylphenidate, which slows DA clearance (Izenwasser et al 1990). Slowed clearance can 
increase basal DA concentrations and increase the duration of phasic events (Volkow et al 2001; 
Wu et al 2002; Heien et al 2005; Montgomery et al 2007). If ADHD is caused by an increase in 
DA activity, how does further increasing DA signaling mitigate symptoms? 
Parkinson’s disease presents another paradox to the ‘fast-type’ model. Parkinson’s 
disease is highlighted by a 90% decrease in striatal DA terminal density (Bernheimer et al 1973; 
Robinson and Whishaw 1988). Striatal denervation leads to loss of motor control and dementia 
in the patient, implementing DA signaling in these functions (Albin et al 1989; Maneuf et al 
1997). Parkinson’s disease is successfully treated with L-3,4-dihydroxyphenylalanine (L- 
DOPA), a DA precursor. L-DOPA is converted into DA by the aromatic L-amino acid 
decarboxylase enzyme. This enzyme is found in several cell lines, so L-DOPA can be converted 
into DA even in the absence of DA terminals (Melamed et al 1980). The absence of DA 
terminals means that the DA produced from L-DOPA is not released by phasic events, nor 
cleared by DAT. Therefore, it is hypothesized that DA leaks into the extracellular space 
increasing the basal DA concentration, a tonic DA signaling event (Melamed et al 1980; Hefti et 
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al 1981; Keller et al 1988; Zigmond et al 1992). If tonic DA signaling does not occur during 
normal DAergic function, why is it necessary in the treatment of Parkinson’s disease? 
This dissertation re-examines the striatal DA system, focusing on the oft ignored slow-
type responses. We discover that the slow-type response is not a product of diffusion caused by a 
lack of DA terminals in the vicinity of the CFE. Rather the slow-type response is caused by local 
DA terminals under a tonic DA signal. As such, we conclude that the striatal DAergic pathway is 
actually a dual pathway that signals on both short (phasic) and long (tonic) time scales. This 
discovery will revolutionize the way we view striatal DA function and pathologies.  
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2.0 TONIC AUTOINHIBITION CONTRIBUTES TO THE HETEROGENEITY OF 
EVOKED DOPAMINE RELEASE IN THE RAT STRIATUM 
 
2.1 ABSTRACT 
 
Electrically evoked dopamine release as measured by voltammetry in the rat striatum is 
heterogeneous in both amplitude and temporal profile.  Previous studies have attributed this 
heterogeneity to variations in the proximity of the voltammetric electrode to DA terminals.  We 
reach the alternate conclusion that local variations in autoinhibition is the major contributor to 
this phenomenon.  We demonstrate that low-amplitude, slow evoked DA responses in the 
striatum occur even when recording electrodes are close to DA terminals.  Moreover, the 
responses are affected by the D2 agonist and antagonist, quinpirole and raclopride, respectively, 
in a manner consistent with the known functions of presynaptic D2 autoreceptors.  Whereas 
recent voltammetric studies have focused attention on high-speed DA transients, we find that 
autoinhibited responses are prevalent in the dorsal striatum.  In these experiments, autoinhibition 
preceded the electrical stimulation, which is consistent with prior reports from our laboratory that 
the striatum contains a tonic pool of extracellular DA at basal concentrations sufficient to occupy 
D2 receptors.  We conclude that the striatum contains DA terminals operating on multiple time 
courses due to spatial fluctuations in autoinhibitory tone.  We provide direct, real-time 
observations of the functional consequence of tonic and phasic DAergic signaling in vivo. 
 
15 
 
2.2 INTRODUCTION 
 
Central dopamine (DA) neurons exhibit a broad functional diversity that underlies their role in 
numerous pathologies, including substance abuse (Phillips et al 2003b), schizophrenia (Abi-
Dargham et al 2000), and attention deficit hyperactivity disorders (Salahpour et al 2008).  The 
mechanisms responsible for DA’s diversity of function and dysfunction are a matter of 
longstanding interest.  The anatomical compartmentalization into the nigrostriatal and 
mesolimbic DA systems is well known (Carli et al 1985; Carr and White 1986; Horvitz 2000).  
Furthermore, DA systems operate on multiple time scales to selectively encode function.  
Accordingly, rapid DA signaling encodes reward and learning whereas slower DA signaling 
appears more relevant to motor function (Schultz 2007).  However, the literature does not 
contain direct observations of extracellular DA engaged in both rapid and slow signaling. 
Fast-scan cyclic voltammetry (FSCV) has revealed a wealth of information on the role of 
rapid extracellular DA transients in reward and learning (Wightman and Robinson 2002).  DA 
transients are produced by burst firing of DA neurons in response to salient stimuli (Schultz 
1998).  On the other hand, DA neurons also exhibit tonic firing (Grace 1991; Benoit-Marand et 
al 2001; Venton et al 2003).  The low levels of DA release associated with tonic firing are 
challenging to detect (Venton et al 2003) and less amenable to direct investigation.  In addition, 
the dopamine transporter (DAT) contributes to DA release (Lonart and Zigmond 1991; 
Falkenburger et al 2001).  In our hands (Kulagina et al 2001; Borland and Michael 2004; Mitala 
et al 2008), FSCV shows that DAT-mediated release produces a tonic extracellular DA 
concentration in the rat striatum sufficient to occupy DA receptors (Grigoriadis and Seeman 
1985), including the presynaptic D2 autoreceptors that affect DA release, synthesis, and uptake 
(Usiello et al 2000; Benoit-Marand et al 2001; Rougé-Pont et al 2002).  This is a surprising 
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result, however, as existing literature suggests that DA terminals are not autoinhibited under 
basal conditions (Garris et al 1994; Garris and Wightman 1995; Benoit-Marand et al 2001). 
For example, D2 antagonists increase evoked DA release upon prolonged electrical 
stimulation of the medial forebrain bundle (MFB) (May and Wightman 1989b; May and 
Wightman 1989a) but do not affect DA release evoked by brief (1- or 4-pulse) stimuli (Garris et 
al 1994; Garris and Wightman 1995).  The absence of an effect on brief stimulus responses 
implies an absence of autoinhibition under basal conditions.  Similarly, haloperidol modestly 
affects DA release evoked by 3-pulse stimuli unless the brief stimuli are delivered momentarily 
after a conditioning prestimulus (Benoit-Marand et al 2001).  The prestimulus transiently evokes 
autoinhibition, implying again that autoinhibition is weak or absent under basal conditions.   
However, evoked DA release is a highly heterogeneous phenomenon (May and 
Wightman 1989b; May and Wightman 1989a).  Consequently, only a subset of optimized 
recording locations illustrate the point that DA terminals are not normally autoinhibited.  Until 
now the heterogeneity of evoked DA release has been attributed to a variable DA innervation of 
terminal fields, such that some recording locations are close to DA terminals whereas others are 
not.  Consequently, it has become common practice to adjust the position of recording electrodes 
to, presumably, locate DA terminals (Garris et al 1993).  This practice, combined with other 
refinements of the FSCV technology, has produced detailed knowledge of both evoked and 
naturally occurring sub-second DA transients, fostering seminal insights into their physiological 
and functional significance(Robinson et al 2001; Phillips et al 2003b; Roitman et al 2004; Stuber 
et al 2005).  On the other hand, relatively little attention has been paid to sites that do not exhibit 
transient DA release. 
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The literature suggests that recording sites that do not produce transient DA release are 
those where DA terminals are absent, such as the “non-DA” sites revealed by 
immunohistochemical studies (Venton et al 2003).  Evoked responses in such locations exhibit 
low amplitudes and sluggish temporal features, which have been attributed to diffusional 
distortions of the DA signal evoked at terminals remote from the electrode (i.e. the electrode 
missed its intended target) (May and Wightman 1989b; Garris et al 1994).  However, herein we 
provide two lines of evidence that such responses derive instead from autoinhibition of DA 
terminals.  First, we show that several qualitative features of the responses are inconsistent with 
diffusional phenomena.  Second, we show that the D2 drugs, raclopride and quinpirole, affect the 
responses in a manner consistent with the known functions of D2 autoreceptors (Usiello et al 
2000; Benoit-Marand et al 2001; Rougé-Pont et al 2002).  Our findings clearly show that the 
recording sites are not devoid of DA terminals.  Instead, these are sites where DA terminals are 
powerfully autoinhibited even under basal conditions.  Hence, our study provides direct 
voltammetric observations of DA terminals simultaneously engaged in both rapid and slow DA 
signaling depending, at least in part, on the strength of a spatially variable autoinhibitory tone.  
We hypothesize that the autoinhibitory tone derives from the tonic pool of extracellular DA in 
the striatum (Kulagina et al 2001; Borland and Michael 2004). 
 
2.3 METHODS AND MATERIALS 
 
2.3.1 Carbon fiber electrodes 
Single 7-μm diameter carbon fibers (T650, Cytec Carbon Fibers LLC., Piedmont, SC) were 
placed inside borosilicate glass capillaries (dimensions prior to pulling 0.4 mm ID, 0.6 mm OD, 
A-M systems Inc., Sequim, WA). The capillaries were pulled to a fine tip with a vertical 
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micropipette puller (Narishige, Los Angeles, CA) and backfilled with low-viscosity epoxy (Spurr 
Epoxy, Polysciences Inc., Warrington, PA). The exposed carbon fibers were cut to a length of 
400 μm and sonicated in reagent grade isopropyl alcohol (Sigma, St. Louis, MO) containing 
activated carbon (Fisher Scientific, Fair Lawn, NJ) for 30 minutes (Bath et al 2000). A droplet of 
mercury in the electrode barrel established electrical contact between the fiber and a nichrome 
contact wire (Goodfellow, Huntingdon, Cambridgeshire, UK). 
 
2.3.2 Fast scan cyclic voltammetry 
FSCV was conducted with an EI 400 high-speed potentiostat (originally constructed by Ensman 
Instruments but presently available from ESA Inc., Chelmsford, MA) and the program “CV Tar 
Heels v4.3” (courtesy of Dr. Michael Heien, Department of Chemistry, Pennsylvania State 
University).  The resting potential was 0 V vs Ag/AgCl and the voltammetric waveform 
consisted of three linear potential sweeps to +1 V, -0.5 V, and back to 0 V at a sweep rate of 400 
V/s. The scans were performed at 10 Hz.  The DA oxidation current was recorded between 0.5 
and 0.7 V during the first sweep.  DA voltammograms were obtained by background subtraction.    
 
2.3.3 Electrode calibration 
Electrodes were pre- and post-calibrated in a flow cell with gravity fed artificial cerebral spinal 
fluid solution (aCSF: 1.2mM Ca2+, 152mM Cl-, 2.7mM K+, 1.0mM Mg2+, 145mM Na+, pH 7.4).  
Electrodes with rapid DA response times were identified by pre-calibration: electrodes exceeded 
85% of their steady-state DA signal in less than 300 ms, i.e. by the third measurement after a 
step change in DA concentration.  Conversion of in vivo oxidation currents to DA concentrations 
was based on post-calibration results. Standards for calibration were prepared by dissolving 
dopamine HCl (Sigma Aldrich, St. Louis, MO) in aCSF. 
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2.3.4 Animals 
Male Sprague-Dawley rats (250-350g) (Hilltop, Scottsdale, PA) were anesthetized with 
isoflurane (2% by vol.) and placed in a stereotax (David Kopf Instruments, Tujunga, CA) with 
the incisor bar raised 5 mm above the interaural line (Pellegrino et al 1979).  A heating blanket 
(Harvard Apparatus, Holliston, MA) maintained body temperature at 37oC.  A twisted, bipolar, 
stainless steel stimulating electrode was placed over the medial forebrain bundle (MFB) (from 
bregma: 1.6 mm lateral, 2.2 mm posterior, 8.0 mm below dura).  A carbon fiber microelectrode 
was placed in the ipsilateral striatum (from bregma: 2.5 mm lateral, 2.5 mm anterior, initially 4.5 
mm below dura).  The final position of the stimulating electrode was set by lowering it until 
evoked DA release was observed in the striatum: this is a well-established adopted protocol for 
locating the tip of the stimulating electrode so as to activate ascending DAergic fibers (Ewing et 
al 1983; Kuhr et al 1984; Heien et al 2005). 
 
2.3.5 Electrical stimulation 
The stimulus was an optically isolated, constant-current, biphasic waveform (frequency 60 Hz, 
pulse height 270 µA, pulse width 2 ms).  Single train and multiple train stimuli were employed 
for this study.  Single trains lasted between 0.2 s and 5 s in duration, as indicated below.  During 
multiple train stimuli, four 1-s trains were delivered with 2-s or 4-s intervals between the trains. 
Stimuli were delivered before and 30 min after drug administration. 
 
2.3.6 Drugs 
Raclopride tartrate (Sigma Aldrich, St. Louis, MO) was administered at a dose of 2 mg/kg, i.p. 
dissolved in phosphate buffered saline (155mM Na+, 155mM Cl-, 100mM phosphate, pH 7.4). 
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(-)Quinpirole hydrochloride (Sigma Aldrich, St. Louis, MO) was administered at a dose of 1 
mg/kg, i.p. dissolved in phosphate buffered saline. 
 
2.3.7 Modeling 
Evoked DA responses were simulated with Wightman’s model, embodied in the following 
equation (Wightman et al 1988):  
Equation 1: 
Mex
ex
p
ex
KDA
DAVDAf
dt
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−=
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where [DA]ex represents the extracellular DA concentration, f is the stimulus frequency, [DA]p is 
the concentration of DA released-per-pulse, Vmax is the maximum velocity of DA uptake, and 
KM is the DAT Michaelis constant.  The effects of diffusion on [DA]ex were examined by 
convoluting the output of Equation 1 with Fick’s second law of diffusion.  The convolution was 
implemented by a finite element algorithm in Excel.  We have described the use of finite element 
algorithms in several previous papers (Lu et al 1998; Yang et al 1998), so the details are omitted 
here.  Finite element algorithms for solving diffusion equations are well known (Bard and 
Faulkner 2001).  
 
2.3.8 Data analysis 
Voltammetric currents recorded in vivo were converted to DA concentrations by post-calibration 
of the electrodes.  During multi-train stimuli, the voltammetric signal occasionally did not return 
to baseline during the interval between trains.  In these cases, voltammetric signals were re-
zeroed at the start of each stimulus train.  Pre- and post-drug response amplitudes during 
consecutive stimulus trains were analyzed by means of two-way ANOVA. 
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2.4 RESULTS 
 
2.4.1 Heterogeneity of evoked dopamine release 
As previously reported (May and Wightman 1989b; May and Wightman 1989a), electrical 
stimulation of DAergic fibers in the MFB evokes heterogeneous DA release in the ipsilateral 
striatum.  The two stimulus responses in Fig 2.1 were recorded using identical voltammetric 
procedures in two different rats.  The stimulus durations were 200 ms (12 pulses) and 1 s (60 
pulses) in Figs 2.1A and 2.1B, respectively.  In each case, a similar amplitude of DA release was 
evoked, ~1.7 µM in these examples, despite the 5-fold difference in stimulus duration.  In some 
cases (Fig 2.1A) the evoked response rises rapidly when the stimulus begins and falls 
immediately when the stimulus ends.  In other cases (Fig 2.1B) the response rate is slow initially 
(arrow 1) but increases as the stimulus continues (arrow 2).  There is no sign of the response rate 
increasing in Fig 2.1A.  Instead, the response rate decreases slightly, as the DA concentration 
after 200 ms of stimulation is less than double the concentration after 100 ms (diamond). 
In the past, a temporal profile such as the one illustrated in Fig 2.1B (a slow initial rise 
followed by a faster subsequent rise) was attributed to diffusional phenomena, giving rise to the 
view that the electrode was not positioned near DA terminals.  However, in this study we show 
that several other attributes of these evoked responses are inconsistent with this explanation.  For 
example, in the event that the appearance of DA at the electrode is delayed by diffusion, then the 
disappearance of DA at the end of the stimulus should also be delayed (see also Fig 2.8, below).  
This is because, in the event the electrode is not close to DA terminals, DA molecules must 
undergo diffusion before encountering the dopamine transporter (DAT).  In previous reports 
(Kawagoe et al 1992), a delay at the end of the stimulus has been called an “overshoot.”  
However, there is no overshoot in the example of Fig 2.1B.  Instead, the DA signal decreases on 
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the first post-stimulus measurement (arrow 3).  The rapid onset of DA clearance indicates that 
the electrode is positioned near DA terminals, as DAT is only found on DA terminals. 
 
2.4.2 Hybrid evoked responses 
Variable response profiles also arise within individual animals (Fig 2.2).  The example in 
Fig 2.2, which we refer to as a hybrid response, exhibits an initial rapid rise in ECS DA when the 
stimulus starts that ends after 200 ms.  The response falls and then increases again but at a slower 
rate than before.  Hybrid responses reveal the simultaneous detection of DA from terminals 
exhibiting heterogeneous behaviors within the recording site of a single electrode.  The hybrid 
responses confirm that the heterogeneity of response profiles are not attributable to any 
instrumental factors, such as the response time or sensitivity of the voltammetric electrode.   
The response reported in Fig 2.1A was from a site exhibiting a hybrid response: the 
stimulus was shortened to 200 ms to isolate the rapid signal component. 
 
2.4.3 Classification of response profiles 
For the sake of clarity, we seek an objective way to classify the heterogeneous response profiles.  
A convenient way to do this is based on whether or not the rate of evoked release increases 
during the stimulus, as in Fig 2.1B.  We classify such responses as “slow-type” because the rate 
of release is initially slow.  Responses that rise linearly, and that sometimes show a decrease in 
the rate of appearance of DA (Fig 2.1A), are classified as “fast-type”.  Although it is generally 
true that, with a stimulus of similar frequency and duration, fast-type responses exhibit larger 
amplitudes than slow-type responses, this classification scheme is not based on the amplitude.  
Since it is easy to identify responses that exhibit an increase in the rate of evoked release during 
a stimulus, this classification scheme is objective. 
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Figure 2.1 Kinetic heterogeneity of evoked DA release in the rat striatum.   
The symbols mark the start (circles) and finish (triangles) of the stimuli.  The evoked change in extracellular DA 
was recorded by FSCV with 400-mm long carbon fiber microelectrodes. (A) A fast-type response: DA increases 
rapidly during the stimulus and falls rapidly after the stimulus. The amount of DA evoked after the first 6 stimulus 
pulses (diamond) is more than half of the amount of DA evoked after 12 pulses (triangle), indicating that the rate of 
DA release is decelerating. (B) A slow-type response: evoked DA release begins slowly (arrow 1) and accelerates as 
the stimulus continues (arrow 2). At the end of stimulation the signal returns toward baseline immediately (arrow 3), 
showing no signs of overshoot. 
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Figure 2.2 An electrode location exhibiting both fast-type and slow-type release.  
This hybrid-type response has two peaks. The slope of the ascending part of the first peak is steeper than the second 
peak counterpart. The rapid rise of the first peak demonstrates a fast-type response, while the second peak has a 
slow-type response. 
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2.4.4 Evoked dopamine release during multiple stimulus trains 
We characterized fast, slow, and hybrid responses using multiple trains of MFB stimulation (Figs 
2.3-2.6).  In these figures, circles and triangles mark the start and end, respectively, of each 
stimulus train.  To compare the responses to individual trains, we re-zeroed each response at the 
beginning of each train (notice that the circle symbols denoting the start of each train all fall on 
the x-axes of the figures and there is a break in each trace 1 s before each train) 
Most experiments involved 1-s stimulus trains separated by 2-s intervals.  When the first 
train evoked a fast-type response (Fig 2.3A), subsequent trains evoked descending response 
amplitudes.  These descending amplitudes highlight the tendency for the rate of evoked release 
to slow down when the initial rate is high.  This slow-down phenomenon has been reported 
before and attributed to an exhaustion effect and/or autoinhibition resulting from the evoked 
increase in extracellular DA (Garris et al 1994; Benoit-Marand et al 2001).  
On the other hand, when the first train evoked a slow-type response (Fig 2.3B), 
subsequent trains evoked ascending response amplitudes.  In the example of Fig 2.3B, the rate of 
evoked release increased during the first train and each subsequent train evoked consecutively 
faster DA release.  Hence, when the interval between trains is 2 s, the increase in the rate of 
evoked DA release carries over from one train to the next.  This carry-over effect is short-lived, 
however, as it is almost abolished if the interval between trains is increased to 4 s (Fig 2.3C).   
The individual slow-type responses in Figs 2.3B and 2.3C are representative examples: Fig 2.3D 
summarizes normalized slow-type response amplitudes with 2-s and 4-s intervals from 13 
animals (ANOVA; F(1,96) = 61.6; n=13; p<0.00001). In these experiments, there was no need to 
reposition the electrodes to locate slow responses: in our hands, of the fast- and slow-type 
responses, the slow-type is the prevalent one in the rat striatum. 
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Figure 2.3 DA recordings by FSCV during consecutive trains of MFB stimulation.   
(A) Fast-type response during 1-s trains at 2-s intervals.  (B) Slow-type response during 1-s trains at 2-s intervals.  
(C) Slow-type response during 1-s trains at 4-s intervals. (D) Comparison of the normalized amplitudes of the slow-
type responses at 2-s and 4-s intervals: the difference between the 2-s and 4-s groups is significant (ANOVA; F(1,96) 
= 61.6; n=13; p<0.00001). 
 
 
  
27 
 
As mentioned, slow-type responses were previously attributed to diffusion.  Here, 
however, we find that the increased response rate persists across a 2-s interval between the trains.  
This persistence cannot be explained by diffusion (see also Fig 2.8).  Thus, the persistence, along 
with the absence of response overshoots, is inconsistent with the idea that the slow-type 
responses are caused by diffusion. 
Multiple stimulus trains (1-s trains with 2-s intervals between the trains) were used at 
recording sites exhibiting hybrid responses (Fig 2.4).  In the majority of these cases, a fast 
response appears as a leading shoulder superimposed on a subsequent slow response.  The 
leading shoulder was most apparent during the first stimulus train.  We used the evoked 
amplitude after the 12th stimulus pulse (black diamonds in Fig 2.4A) to quantify the fast 
responses.  The amplitude after the 12th pulse decreased from train-to-train, consistent with the 
decrease in the rate of evoked release associated with fast-type responses.  We also examined the 
response to 12-pulse stimulus trains (200-ms trains with 1.8-s intervals between the trains) and 
again observed a decrease in the rate of evoked release (Fig 2.4B).  Figure 2.4C shows averaged 
DA amplitudes for three animals after the 12th and 60th pulse during a 1-s train, 2-s interval 
stimulation and a 0.2-s train, 1.8-s interval stimulation. The pattern of evoked release at the 
different time-points is significantly different (ANOVA; F(2,24) = 44.6; n=3; p<0.00001).  
However, a Tukey post-hoc test reveals that the 12th pulse and 0.2-s train responses are not 
significantly different, suggesting that the fast-type response functions independently of the 
slow-type response.  In order to record these hybrid responses, it was necessary to optimize the 
placement of the recording location.  Even with optimization, we were unable to locate hybrid 
responses in all animals.   Thus, sites yielding hybrid responses are relatively rare compared to 
those that yield slow responses. 
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Figure 2.4 Kinetic hybrid responses during consecutive trains of MFB stimulation.  
(A) During 1-s trains at 2-s intervals the fast-type signal component appears as a leading shoulder on the response.  
The signal recorded after 12 stimulus pulses (diamonds) was used to quantify the amplitude of the fast signal 
component.  The signal recorded after 60 pulses (squares) was used to quantify the slow component. (B) DA during 
200-ms (12-pulse) trains at 1.8-s intervals: these short trains isolate the fast signal component. (C) Normalized 
response amplitudes: according to ANOVA the group effect is significant (ANOVA; F(2,24) = 44.6; n=3; p<0.00001); 
according to the Tukey post-hoc test, there is no difference between the responses after 12 pulses during 1-s trains 
and the responses evoked by 200-ms trains. 
  
29 
 
2.4.5 The role of the dopamine D2 receptor 
The D2 receptor antagonist, raclopride (2 mg/kg i.p), converts slow-type responses to fast-type 
responses (Fig 2.5).  In the example of Fig 2.5A, the pre-raclopride response (1-s trains with 2-s 
intervals between trains) is slow-type.  However, the post-raclopride response in the same 
recording site is fast-type.  Raclopride eliminated the initial period of slow release and later 
trains evoked responses with descending amplitudes.  In multiple animals (n=5), raclopride 
consistently and substantially increased the amplitude of the response to the first stimulus train 
and abolished the increase in the response amplitude during subsequent trains (Fig 2.5B).   
In every case involving slow-type responses, raclopride increased the amplitude of the 
DA measurement from the very beginning of the first stimulus train, i.e. after 12 stimulus pulses.  
Pre-raclopride, evoked DA release was often not detectable after the first 12 stimulus pulses. 
Hence, the effect of raclopride is not dependent upon the evoked release of DA. In this important 
regard, our results are different from the 1-to-4 pulse results of Wightman and Gonon (Garris et 
al 1994; Benoit-Marand et al 2001).  To quantify this effect, we measured the slope of the 
evoked response between 100 and 300 ms (6-18 pulses) after the start of each stimulus train (Fig 
2.5C). In five animals raclopride consistently and significantly increased the initial slope of the 
DA signal compared to the pre-drug response (ANOVA; F(1,32) = 21.9; n=5; p<0.0001). These 
observations carry two important meanings.  First, they show that the slow responses, when they 
occur, are a consequence of autoinhibition that occurs due to a preexisting tone of DA on D2 
receptors, i.e. basal DA as opposed to evoked DA.  Second, they show that the electrode is 
positioned near DA terminals as, within the temporal resolution of these experiments (100 ms), 
there is no delay in the arrival of DA at the electrode post-raclopride.  The delay observed pre-
raclopride, therefore, is logically attributable to the electrode being positioned close to 
autoinhibited DA terminals.   
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Raclopride affects both DA release and clearance (Greco et al 2006).  So, we wished to 
establish whether the effect of raclopride is due to a change in DA release or DA clearance.  For 
this purpose, we adjusted the stimulus duration to establish similar evoked amplitudes pre- and 
post-raclopride and then aligned the responses at the end-point of the stimuli (Fig 2.5D).  This 
procedure revealed no consistent effect of raclopride on DA clearance, suggesting the effects 
reported here are derived from alterations in evoked release. 
The D2R agonist, quinpirole (1 mg/kg i.p.), consistently and significantly extended the 
initial period of slow evoked release (Fig 2.6): evoked release was not detected during the first 
stimulus train (Fig 2.6A).  This clearly shows that a delay in the evoked response can be due to 
the activation of inhibitory receptors rather than an absence of DA terminals.  Later stimulus 
trains produced ascending response amplitudes, as before.  The post-quinpirole amplitudes were 
significantly lower than the pre-drug amplitudes (Fig 2.6B; ANOVA; F(1,32) = 29.1; n=5; 
p<0.0001).  As before, we adjusted the stimulus durations to match the pre- and post-quinpirole 
amplitudes and aligned the responses at their end-points (Fig 2.6C).  Quinpirole had no 
systematic effect on DA clearance.  Interestingly, aligning the responses in this way produced 
similar temporal profiles of evoked release.  Thus, quinpirole extended the initial slow phase of 
evoked release but did not thereafter alter the time course of the subsequent response. 
Quinpirole (1 mg/kg i.p.) abolishes the fast component of hybrid responses (Fig 2.7A).  
The fast component of hybrid responses was isolated with a short 200 ms stimulus (12 pulses).  
Quinpirole (1 mg/kg i.p.) abolished all 12-pulse stimulus responses (Fig 2.7B and 2.7C).  After 
quinpirole, even when the stimulus duration was extended, only slow-type evoked responses 
(slow initial responses rates and subsequent facilitation, Fig 2.7A) are observed.  These results 
confirm that activation of D2 receptors abolishes the fast component of these responses. 
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Figure 2.5 Raclopride accelerates DA release.  
(A) Raclopride (2 mg/kg i.p.) converts slow-type responses (pre-drug, solid line) to fast-type responses (post-drug, 
dashed line). (B) The effect of raclopride is significant (ANOVA; F(1,32) = 52.86; p<0.00001). Pre-drug there was a 
significant difference between the responses to the consecutive trains, but raclopride abolished this difference 
(ANOVA; F(3,32) = 0.88; n=5; p>0.5). (C) The effect of raclopride on the initial rise of the DA signal is also 
significant (ANOVA; F(1,32) = 21.9; n=5; p<0.0001).  Raclopride removed the delay present in the pre-drug signal, 
causing DA signals that increased immediately upon stimulation.  (D) The duration of pre- and post-drug stimuli 
were adjusted to produce a similar maximal amplitude. Then the responses were aligned at the end of the stimulus to 
permit a comparison of the clearance kinetics. Raclopride had no consistent effect on DA clearance, suggesting that 
the effects of raclopride noted in this figure are due to changes in the velocity of evoked DA release. 
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Figure 2.6 Quinpirole further delays slow-type evoked DA release.  
(A) Quinpirole decreased the response amplitudes during 1-s trains at 2-s intervals. However, quinpirole did not 
prevent the acceleration of evoked DA release.  (B) The effect of quinpirole on the normalized response amplitudes 
is significant (ANOVA; F(1,32) = 29.1; n=5; p<0.0001). Quinpirole did not remove the significant difference between 
the response amplitudes to consecutive trains (ANOVA; F(3,32) = 6.8; n=5; p<0.002). (C) The duration of pre- and 
post-drug stimulus responses were adjusted in order to evoke similar response amplitudes, thus the start of 
stimulation pre-drug (closed circle) and quinpirole (open circle) were staggered. Quinpirole delayed the onset of 
evoked release but thereafter did not alter the kinetics of evoked DA release or the kinetics of DA clearance after the 
stimulus.   
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Figure 2.7 Quinpirole converts hybrid responses to slow-type responses.  
(A) Before quinpirole, evoked release begins without delay after the onset of stimulation (60 Hz).  Quinpirole delays 
the onset of evoked release and diminishes the amplitude of release evoked by the first 12 stim pulses (solid 
diamonds).  (B) Quinpirole abolishes 12-pulse stim responses. (C) The decrease in DA release evoked by 12 stim 
pulses after quinpirole is significant (ANOVA: F(1,3) = 100.8; n = 3; p<0.001). 
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2.4.6 Insights from Wightman’s model of evoked release 
At several points during this paper, we have relied on the concept that the slow-type responses 
exhibit features inconsistent with diffusion.  Here, we explain this point in more detail. 
The simplest form of Wightman’s model, i.e. equation 1 with constant parameters 
([DA]p, Vmax, and KM), is incapable of reproducing responses with a slow initial rate that later 
increases (as in Fig 2.1B).  The modeled responses all slow down as the stimulus proceeds (Fig 
2.8A).  The examples of Fig 2.8A were generated with standard parameter values from the 
literature.  This behavior has a very simple origin: the release term, 𝑓 ∗ [𝐷𝐴]𝑝, is constant but the 
uptake term, 𝑉𝑚𝑎𝑥∗[𝐷𝐴]𝑒𝑥[𝐷𝐴]𝑒𝑥+𝐾𝑀 , increases as [DA]ex increases.  Thus, as the stimulus proceeds, [DA]ex 
increases but so does the rate of uptake, so the response has to slow down.   
When the simulated responses are convoluted with diffusion, they do speed-up (Fig 
2.8B).  In the example of figure 2.8B, a simple response is convolved with diffusion over a 
distance of 15 µm using the DA diffusion coefficient measured in the rat striatum (Nicholson and 
Rice 1991).  Indeed, the convolution produces a slow initial response that speeds up as the 
stimulus proceeds (arrow 1).  Qualitatively, there is a good match between the convoluted 
responses and the slow-type voltammetric responses recorded in vivo (e.g. Fig 2.1B).  However, 
the convoluted simulated response exhibits an obvious overshoot at the end of the stimulus 
(arrow 2), which is absent in our in vivo recordings. 
During this study, we made no attempt to fit the convoluted simulations to our in vivo 
results because we do not agree that diffusion causes the slow-type responses.  For the same 
reason, we have made no attempt to use deconvolution to remove diffusional effects from our in 
vivo results.  In past work, deconvolution was employed to remove the effects of diffusion 
through Nafion layers on electrodes (Kawagoe et al 1992).  We did not employ Nafion layers in 
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the present work.  Furthermore, we have here reported examples of fast-type responses, which 
demonstrate that the slow-type responses are not caused by slow electrodes or other instrumental 
factors.  Therefore, we have no justification to apply deconvolution to our results. 
Diffusion also does not explain the train-to-train increases in evoked release 
characteristic of slow-type responses.  In the example of figure 2.8C, the simple model was used 
to simulate a response to four 1-s trains with 2-s intervals between the trains with and without 
convolution (same distance and diffusion coefficient as in Fig 2.8B).  The simple model, with or 
without convolution, does not reproduce the changes in temporal profile and amplitude observed 
in vivo (Fig 2.3B), so we conclude that these observations are not caused by diffusional 
phenomena. 
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Figure 2.8 The Wightman model of dopamine release and diffusion 
(A) Theoretical evoked DA curves using the Wightman model (Vmax = 6 mM/s, KM = 200 nM, [DA]P = 200 nM). 
The modeled curve rises without delay at all stimulus frequencies. (B) The effects of a 15 µm diffusion gap on the 
Wightman model curve (60 Hz). Diffusion causes an initial delay in the DA signal (arrow 1), and an overshoot of 
signal after the end of stimulation (arrow 2). (C)  Modeling 1-s trains, 2-s interval stimulations. The Wightman 
model predicts four equal evoked curves (dashed lines). Diffusion of four identical evoked curves produces four 
signals with similar delays and amplitudes. 
 
  
1 
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2.5 DISCUSSION 
 
The findings of the present study support the conclusion that the slow-type evoked responses 
arise when DA terminals proximal to the recording electrode are autoinhibited by basal 
extracellular DA.  Direct evidence to support this conclusion stems from the ability of the D2 
antagonist, raclopride, to eliminate the slow initial phase of evoked DA release and the ability of 
the D2 agonist, quinpirole, to extend it.  We consider this a tonic, rather than phasic, effect 
because autoinhibition was present prior to the onset of electrical stimulation.  This is consistent 
with our prior reports that the striatal extracellular space contains a tonic pool of DA at 
concentrations sufficient to activate DA receptors (Kulagina et al 2001; Borland and Michael 
2004; Mitala et al 2008).  Our study provides direct, real-time recordings of DA functioning in 
vivo on multiple time scales determined, at least in part, by the efficacy of a local autoinhibitory 
tone.   
 
2.5.1 Diffusion or complex release kinetics? 
May and Wightman (May and Wightman 1989b; May and Wightman 1989a) reported the 
tendency of evoked responses to begin slowly and to speed up with continued stimulations, as we 
have also reported here (Fig 2.1B).  Although May and Wightman speculated that this feature 
might be due to an increase in the rate of evoked release, they attributed it instead to diffusional 
phenomena arising when the recording electrode is remote from DA terminals (May and 
Wightman 1989b).  Other authors have suggested that diffusional phenomena might arise when 
the electrode is surrounded by a zone of dead tissue (Benoit-Marand et al 2007), although our 
electron microscopy study shows that any that any dead zone is too small to create severe 
diffusional distortion (Peters et al 2004).  As we have mentioned, however, other features of the 
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slow type responses speak against the diffusion-based explanation.  First, the responses do not 
exhibit the expected overshoots at the end of the stimulus trains (Fig 2.1B and 2.8B), which 
shows that the electrode is close to DAT and, therefore, DA terminals.  Second, diffusion does 
not explain the persistence of increased rates of evoked release across the intervals between 
trains (compare Fig 2.3B with Fig 2.8C).  Third, the initial slow phase of release was abolished 
by raclopride (Fig 2.5) and extended by quinpirole (Fig 2.6) and thus stems from a D2R-
mediated control of evoked release. There is no evidence to suggest that diffusion is sensitive to 
D2 receptors.   
 
2.5.2 Other methodological considerations 
Immunohistochemical studies have demonstrated that DA terminal fields contain non-DA sites 
(Venton et al 2003), i.e. sites that lack DA terminals.  However, the electrodes employed for this 
study were 400 µm long, which is very long compared to the dimensions of the non-DA sites 
(less than 10 µm) identified by Venton et al. (2003).  Thus, it is not possible that our DA 
measurements were confined to non-DA sites. Likewise, the slow DA responses were not limited 
by the performance attributes of the voltammetric electrodes.  Slow initial responses gave way to 
more rapid responses, at the same electrode, by virtue of continued electrical stimulation or by 
the administration of raclopride.  On the same grounds, we eliminate the possibility that the slow 
responses stem from poor placement of the stimulating electrode. 
 
2.5.3 Slow type responses are prevalent in the striatum 
 Using 400-µm long electrodes, the recording of slow type responses in the striatum is routine.  
For this reason, we consider the slow type responses to be the prevalent striatal response.  
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Furthermore, since many of the responses recorded during this study were exclusively of the 
slow type, we conclude that these responses occur with a domain size commensurate with the 
length of the electrode.  We did also occasionally observe hybrid responses with a fast type 
response component, but we had to search for these sites.  This portrays the fast sites as the 
comparatively rare DAergic behavior in the striatum and associated with a spatial domain size 
smaller than that of the slow type responses. 
Hence, it is our point of view that the prevalence of the slow type responses in the 
striatum indicates that a majority of DAergic terminals in this brain structure exist under a state 
of tonic autoinhibition.  This point has been overlooked in the previous literature, in part due to 
the attribution of slow type responses to diffusional phenomena.  In an attempt to avoid the 
perceived diffusional distortion of responses, many users of voltammetry optimize the placement 
of their recording electrodes so as to concentrate their studies on fast-type responses.  An 
important insight from our study is that the search for optimized recording sites likely constitutes 
a search for sites were DA terminals are free of autoinhibition.  This explains the contrast 
between our conclusions and those of Wightman (Garris et al 1994) and Gonon (Benoit-Marand 
et al 2001).  On the basis of very brief electrical stimuli (1 to 4 pulses), these authors concluded 
that DA terminals normally experience little or no autoinhibition in the absence of MFB 
stimulation.  However, their studies were performed in fast sites found by optimizing the 
placement of the electrodes, as evidenced by the fact that brief responses were detectable (both 
authors mention that the brief stimuli do not always produce detectable responses).  The fact that 
autoinhibition has been overlooked as a contributing factor in the heterogeneity of the striatal DA 
system can be attributed to the decision to focus attention on fast responses.  
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2.5.4 A comment on stimulus-induced acceleration of evoked DA release 
While autoinhibition provides a clear explanation for the slow initial rate of evoked release, our 
study does not provide an explanation for the acceleration of evoked release that occurs with 
continued stimulation.  While stimulus-induced acceleration of neurotransmitter release is an 
interesting and known phenomenon (Greengard et al 1993), it was not the main focus of the 
present study.  The stimulation frequency we used (60 Hz) is clearly supraphysiological, as DA 
neurons burst around 20 Hz and tonically fire at 1-2 Hz (Grace and Bunney 1984; Benoit-
Marand et al 2001; Hyland et al 2002).  Thus, the details of the release evoked by 60 Hz stimuli 
are not likely to be of direct physiological relevance.  The value of this supraphysiological 
stimulus is its ability to reveal the existence of pre-stimulus autoinhibition, which is the main 
focus of our study.  Since the autoinhibition we describe here is derived from endogenous DA 
present in the extracellular space, we presume that the autoinhibition is physiologically relevant. 
 
2.5.5 The role of autoreceptors 
Our results show that the slow type responses are a consequence of autoinhibition triggered by 
basal DA present in the extracellular space prior to the onset of electrical stimulation.  It is 
important to emphasize that the D2R drugs did not simply alter the magnitude of the slow-type 
responses but also rather dramatically altered their time course.  The D2R antagonist, raclopride, 
caused the DA signal to appear before the onset of pre-raclopride slow-type evoked release (Fig 
2.5).  The D2R agonist, quinpirole, delayed the appearance of the DA signal without 
substantially altering the subsequent dynamics of release or clearance (Fig 2.6).  Thus, we 
conclude that the slow-type kinetics arise when DA terminals are under an autoinhibitory tone 
prior to the initiation of the stimulus. 
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The impact of D2Rs on fast-type evoked DA release has been thoroughly characterized by 
other laboratories in several experimental models (Limberger et al 1991; Kennedy et al 1992; 
Benoit-Marand et al 2001; Phillips et al 2002; Avshalumov and Rice 2003; Kita et al 2007).  A 
main conclusion of those prior studies is that autoinhibition of fast type responses begins only 
after the stimulus itself delivers DA to the extracellular space.  These results are confirmed by 
the ability of the D2R agonist, quinpirole, to convert fast type responses into slow type responses 
(Fig 2.7). Thus, there is a clear contrast in the manner by which autoinhibition affects slow- and 
fast-type behaviors.  However, this contrast is related to differences in D2R expression, since 
both the slow- and fast-type responses are sensitive to D2R agonists and antagonists, although in 
different ways.   
 
2.5.6 The origin of pre-stimulus autoinhibition 
We conclude that the kinetic status of striatal DA terminals, i.e. whether they exhibit fast or slow 
evoked responses, is at least partially determined by the absence or presence, respectively, of 
autoinhibitory tone.  Recently, our laboratory presented FSCV-based evidence for the presence 
in striatal extracellular space of micromolar concentrations of non-evoked DA (Kulagina et al 
2001; Borland and Michael 2004; Mitala et al 2008).  Such DA concentrations are sufficient to 
tonically activate D2R autoreceptors (Grigoriadis and Seeman 1985).  The micromolar 
concentration of DA we reported exceed the low-nanomolar basal DA levels reported by 
microdialysis.  However, several studies have explained that the combined effects of tissue 
damage and DA uptake cause microdialysis to underestimate actual in vivo DA concentrations, 
even when no-net-flux or extrapolation to zero-flow is used (Clapp-Lilly et al 1999; Peters et al 
2000; Bungay et al 2003; Borland et al 2005; Mitala et al 2008).  While our prior studies 
demonstrated the presence of a tonic extracellular DA pool in the striatum, the present study 
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demonstrates the functional significance of that tonic DA pool.   Sites within the striatum 
previously identified as non-DAergic, due to the absence of DA transients, are now reinterpreted 
as sites where tonic DA signaling is taking place. 
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3.0 USING SEGMENTED FLOW TO CONTROL DRUG LEAKAGE FROM THE TIP 
OF DUAL-FUNCTION DOUBLE BARREL PICOSPRTIZER ELECTRODES 
 
3.1 ABSTRACT 
 
Recent studies using fast scan cyclic voltammetry in conjunction with carbon fiber electrodes 
identify unique domains of dopamine terminal function within the striatum. Further exploration 
of these domains requires a device capable of electrode location optimization and temporally 
controlled analyte delivery at the recording site. In this study we use a dual function double 
barrel picospritzer electrode, where the open tip of the picospritzer barrel is immediately adjacent 
to the carbon fiber electrode. This system can deliver controlled volumes of analyte solution at 
optimized recording sites. However, while monitoring current change during both baseline and 
evoked dopamine release at the adjacent carbon fiber electrode we discover that physiologically 
relevant concentrations of analyte leak from the tip of the picospritzer barrel. In order to gain 
temporal control of analyte release we use segmented flow. An air bubble separates the buffer 
solution at the tip of the electrode from the analyte solution in the barrel, preventing analyte 
leakage from the tip. Initial picospritzer ejections compress the air bubble allowing the analyte 
solution to mix into the tip solution. Once the analyte is in the tip solution further picospritzer 
ejections deliver the analyte into the extracellular space. This method prevents the untimed 
delivery of analytes to the extracellular space.  
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3.2 INTRODUCTION 
The Nigrostriatal dopamine pathway is comprised of a relatively small number of dopamine 
(DA) neurons. These cells originate in the substantia nigra, their axons run along the medial 
forebrain bundle, and their terminals innervate the striatum.  This singular physiology suggests a 
system of dopaminergic cells with a singular function. Yet the striatum has a broad functional 
diversity including; substance abuse, schizophrenia, and attention deficit hyperactivity disorder 
(Abi-Dargham et al 2000; Phillips et al 2003b; Salahpour et al 2008).   
Recent studies of the striatal dopamine system using carbon fiber electrodes in 
conjunction with fast scan cyclic voltammetry reveal significant heterogeneity in dopamine 
terminals response to stimulation and drugs (Kita et al 2007; Zachek et al 2010). This 
heterogeneity is linked to the time course of dopamine-2 receptor (D2R) activation via regulation 
of basal DA concentrations by the dopamine transporter (DAT) (Benoit-Marand et al 2001; 
Moquin and Michael 2009; Wang et al 2010; Moquin and Michael 2011). These unique 
populations of terminals co-exist within the striatum, and are accessed by manipulating the 
electrode location, termed ‘electrode optimization’ (Garris et al 1993). Further understanding of 
these domains and their functional relevance will shed new light on the striatal dopamine sytem 
and its disorders.  
A dual function picospritzer electrode system that is mobile and capable of highly 
localized analyte delivery would be a valued tool in the continued study of dopamine sub-
populations. The ability to locally deliver analytes to the detection location will enable isolated 
studies of the effects drugs have on sub-populations of terminals (Kehr et al 1972; Grace and 
Bunney 1985; Kalivas 1993).  Also, analyte delivery devices are required for the administration 
of drugs that do not cross the blood brain barrier (Reese and Karnovsky 1967; Nagy et al 1984). 
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Therefore it is vital to develop an analyte delivery and detection system that is mobile within 
brain tissue, such that sub-populations can be located, identified, and manipulated.  
A picospritzer system is able to deliver sub-second bursts of compressed air (0-100 psi) 
into the back of a pulled glass capillary. The applied pressure forces controlled volumes of fluid 
through the capillary tip. This analyte delivery device has been used in conjunction with a 
separate detection electrode in in vivo and in vitro setups (Cass et al 1993; Cragg et al 2001; 
Daws and Toney 2007; Makos et al 2009). In order to minimize the distance separating the two 
devices, the picospritzer and detection electrode are placed into the sample at an angle with 
respect to each other. This enables picospritzer placement 100 µm from the detection electrode.  
This setup has two problems. First, the orientation of the picospritzer and electrode does 
not allow for electrode optimization. The picospritzer and detection electrode are not parallel so 
electrode optimization changes the distance separating the delivery device and the detection 
electrode.  Second, even at distances of 100-300 µm, there is significant spherical diffusion of 
the analyte from the picospritzer to the tissue at the detection electrode (Bard and Faulkner 2001; 
Daws and Toney 2007). Thus, a large volume of solution must be delivered into the extracellular 
space in order for a small concentration of analyte to reach the detection electrode (Cass et al 
1993).  
In order to overcome these issues, we utilize a double barreled pulled glass capillary 
whose barrel tips are immediately adjacent to each other. One barrel contains a carbon fiber 
detection electrode protruding from the tip and the other barrel ends in an open hole at the tip for 
delivery of an analyte solution. In this study we employ a picospritzer to deliver the analyte 
solution via short bursts of compressed air. Others have used this double barrel system in 
conjunction with iontophoresis (Herr et al 2008). Regardless of the analyte delivery method, 
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placing the delivery device and detection electrode together solves the above issues. First, the 
detector and delivery system move in tandem allowing for electrode optimization. Second, the 
detection electrode is at the site of analyte delivery, enabling detectable analyte delivery that is 
highly localized without diffusional distortions.  
The co-localization of the picospritzer and detection electrode enables accurate 
comparisons of endogenous and exogenous DA clearance kinetics. Prior experiments using 
separated delivery and detection devices measured significantly different rates of exogenous DA 
clearance compared to evoked DA clearance (Cass et al 1993; Cass and Gerhardt 1994; Kiyatkin 
et al 2000; Sabeti et al 2002). The picospritzer electrode resolves this controversy by delivering 
highly localized bursts of exogenous DA at optimized electrode locations. When recorded from 
the same slow-type striatal location, evoked and exogenous DA clear the extracellular space at 
the same rate (Moquin and Michael 2011).  
However, when placed immediately adjacent to the picospritzer tip, the carbon fiber 
electrode baseline signal detects solution leaking from the picospritzer tip into the extracellular 
space. Further, analytes in the tip solution leak into the extracellular space at physiologically 
relevant concentrations. Uncontrolled picospritzer leakage prevents temporal control of analyte 
delivery. We solve this issue by using segmented flow to separate the buffer solution at the tip of 
the electrode from the buffer solution containing drugs in the barrel. Several priming ejections 
compress the air bubble separating the two solutions, allowing them to mix. Once loaded into the 
tip solution, the analyte is delivered into the extracellular space by another picospritzer ejection. 
While this method does not resolve the leak, it enables the current system to release drugs of 
interest in a controlled, time-dependant manner.  
 
47 
 
3.3 METHODS 
 
3.3.1 Double barrel picospritzer electrode system  
Double barrel borosilicate glass capillaries (dimensions prior to pulling 0.68 mm ID, 1.2 mm 
OD, A-M systems Inc., Sequim, WA) were altered by breaking off approximately one inch of 
one of the barrels using a straight edged tungsten carbide glass scoring knife (Wale apparatus 
Co., Hellertown, PA). The single barrel portion of the longer capillary was connected to the 
Picospritzer apparatus. The shorter barrel housed the carbon fiber electrode.  
Carbon fiber electrodes were made by placing a single 7-μm diameter carbon fibers 
(T650, Cytec Carbon Fibers LLC., Piedmont, SC) were placed inside the shorter borosilicate 
glass capillary. The double barrel capillaries were pulled to a fine tip with a vertical micropipette 
puller (Narishige, Los Angeles, CA). The tips of the pulled barrels stayed together forming a 
single point. The pulled glass formed a seal around the carbon fiber and left an open hole at the 
tip of the picospritzer barrel (Fig 1). The electrode barrel was backfilled with low-viscosity 
epoxy (Spurr Epoxy, Polysciences Inc., Warrington, PA). The exposed carbon fibers were cut to 
a length of 400 μm. A droplet of mercury in the electrode barrel established electrical contact 
between the fiber and a nichrome contact wire (Goodfellow, Huntingdon, Cambridgeshire, UK). 
Picospritzer barrels were prepped for drug delivery by placing the tip of the double barrel device 
into a beaker of artificial cerebral spinal fluid solution (aCSF: 1.2mM Ca2+, 152mM Cl-, 2.7mM 
K+, 1.0mM Mg2+, 145mM Na+, pH 7.4). Capillary action pulled the solution up the open tip of 
the picosprtizer barrel. A drug solution (either DA or raclopride in aCSF) was backfilled into the 
picospritzer barrel. Initial experiments mixed the aCSF and drug solutions in the barrel such that 
they became one solution. Later experiments (when noted) separated the two solutions with an 
air bubble 1-1.5 mm in length.   
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3.3.2 Fast scan cyclic voltammetry 
 FSCV was conducted with an EI 400 high-speed potentiostat (originally constructed by Ensman 
Instruments but presently available from ESA Inc., Chelmsford, MA) and the program “CV Tar 
Heels v4.3” (courtesy of Dr. Michael Heien, Department of Chemistry, University of Arizona).  
The rest potential was 0 V vs Ag/AgCl and the voltammetric waveform consisted of three linear 
potential sweeps to +1 V, -0.5 V, and back to 0 V at a sweep rate of 400 V/s. The scans were 
performed at 10 Hz.  The DA oxidation current was recorded between 0.5 and 0.7 V during the 
first sweep.  DA voltammograms were obtained by background subtraction.    
 
3.3.3 Exogenous analyte delivery 
Analyte solutions were prepared by dissolving the analyte in aCSF. Dopamine HCl or raclopride 
tartrate (Sigma Aldrich, St. Louis, MO) were dissolved at concentrations of 25 mM or 2 mM 
respectively. The analyte solution was delivered from the picospritzer tip using a picospritzer III 
system (Parker Hannifin, Fairfield, NJ). The picospritzer was attached to the single barrel portion 
of the longer capillary. Solutions were ejected from the tip of the picospritzer barrel using high 
pressure nitrogen (10-30 psi). Pressure ejection lasted 0.2 s to 30 s. Injections of DA were 
monitored using FSCV and the adjacent carbon fiber electrode.  
 
3.3.4 In beaker experiments  
The picospritzer barrel was filled with an aCSF solution in the tip, and an aCSF and DA solution 
in the barrel. The Picospritzer electrodes were connected to the picospritzer and electrochemical 
systems and placed in a beaker filled with phosphate buffered saline (PBS: 155mM Na+, 155mM 
Cl-, 100mM phosphate, pH 7.4). The fast scan cyclic voltammetry was used to monitor current 
changes at the carbon fiber electrode during 30 s picospritzer ejections at 30 psi. 
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3.3.5 In vivo experiments  
Male Sprague-Dawley rats (250-350 g) (Hilltop, Scottsdale, PA) were anesthetized with 
isoflurane (2% by vol.) and placed in a stereotax (David Kopf Instruments, Tujunga, CA) with 
the incisor bar raised 5 mm above the interaural line (Pellegrino et al 1979).  A heating blanket 
(Harvard Apparatus, Holliston, MA) maintained body temperature at 37oC.  A twisted, bipolar, 
stainless steel stimulating electrode was placed over the medial forebrain bundle (MFB) (from 
bregma: 1.6 mm lateral, 2.2 mm posterior, 8.0 mm below dura).  A picospritzer electrode was 
placed in the ipsilateral striatum (from bregma: 2.5 mm lateral, 2.5 mm anterior, initially 4.5 mm 
below dura).  The final position of the stimulating electrode was set by lowering it until evoked 
DA release was observed in the striatum: this is a well-established adopted protocol for locating 
the tip of the stimulating electrode so as to activate ascending DAergic fibers (Ewing et al 1983; 
Kuhr et al 1984; Heien et al 2005). 
 
3.3.6 Electrical stimulation  
The stimulus was an optically isolated, constant-current, biphasic waveform (frequency 60 Hz, 
pulse height 270 µA, pulse width 2 ms).  Single trains lasting 3s in duration were used to 
determine the rate of dopamine release at each electrode location.   
 
3.3.7 Electrode calibration 
Electrodes were post-calibrated in a flow cell with gravity fed aCSF.  Conversion of in vivo 
oxidation currents to DA concentrations was based on post-calibration results. Standards for 
calibration were prepared by dissolving dopamine HCl (Sigma Aldrich, St. Louis, MO) in aCSF. 
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3.3.8 Data analysis 
Voltammetric currents recorded in vivo were converted to DA concentrations by post-calibration 
of the electrodes. The maximum amplitudes of evoked or exogenous DA were measured using 
the DA oxidation potential (~650 mV) at the end of each event.  The ejection of aCSF was 
measured at a non-DA redox potential (200 mV). ANOVA was used to determine the statistical 
significance of maximum peak amplitudes.  
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Figure 3.1 Scanning electron microscope image of the picospritzer electrode tip 
The bottom barrel contains the carbon fiber microelectrode. The top barrel ends in an open tip. Analytes are 
delivered from the tip directly at the recording site by means of the Picospritzer III pressure ejection system. 
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3.4 RESULTS 
 
3.4.1 Picospritzer destabilizes electrode baseline 
Using fast scan cyclic voltammetry, a carbon fiber electrode detects fluctuations in current 
caused by chemical changes on the electrode surface and concentration changes of electroactive 
species in solution. A stable baseline indicates that both the electrode surface and analyte 
concentrations are unchanged. Consistent with previous studies, single barrel carbon fiber 
electrodes placed into the striatum of an anestitized rat quickly equilibrate, achieving a steady 
baseline signal (Phillips et al 2003a; Robinson et al 2003; Borland and Michael 2004; Heien et al 
2005; Wightman et al 2007). In our hands baseline recordings from single barrel electrodes are 
stable on the order of minutes and contain signal fluctuations on the order of 0.1- 0.2 µM from 
baseline DA (Fig 2A). This result demonstrates the stability of the recording electrode and the 
constancy of the striatal extracellular fluid that the electrode samples.  
When the same experiment is repeated with a picospritzer electrode containing an aCSF 
solution at the picospritzer tip, the baseline signal is not stable.  These electrodes record extreme 
signal fluctuations vacillating more than 1 µM from baseline in a matter of seconds (Fig 3.2A). 
Cyclic voltammograms do not correspond to any identifiable redox species, e.g. dopamine (data 
not shown). Fluctuations in current are detected in all double barrel electrodes, but the timing 
and amplitude of fluctuation is not consistent, and thus smoothed by averaging (Fig 3.2A – 
black). These fluctuations suggest that either the carbon fiber or the extracellular concentration 
of electroactive species in the extracellular space is rapidly changing. However, the single barrel 
experiments demonstrate that the electrode and extracellular solution are stable. The only 
difference between the single and double barrel experimental setup is the presence of the 
picospritzer tip filled with aCSF at the site of the electrode in the double barrel experiment. 
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Therefore these data suggest that ions freely flow from the picospritzer tip into the extracellular 
solution, altering the extracellular fluid.  
 
3.4.2 Exogenous drugs and evoked dopamine 
A picospritzer tip filled with an aCSF solution containing either dopamine or raclopride was 
placed into the rat striatum. Once the stimulus electrode was placed over the medial forebrain 
bundle, the picospritzer electrode was lowered into a new recording location 0.5 mm below its 
previous location and the dopamine signal from a 3 s evoked stimulation was recorded.  After 5 
minutes a picospritzer ejection delivered the analyte solution into the extracellular space and the 
stimulation was repeated in order to assess the effect of locally administered drugs on evoked 
DA release.  
The administration of exogenous DA in aCSF has no effect on the slow-type evoked 
response profile collected 30 s after the picospritzer ejection. This result is consistent with the 
finding that slow domain short term potentiation is lost when increases in extracellular DA are 
separated by at least 4 s (Fig 2.3C) (Moquin and Michael 2009). Also, these data demonstrate 
that aCSF has no effect on evoked DA. Raclopride ejected from the picospritzer increased the 
rate and magnitude of evoked DA, consistent with raclopride’s action as a D2R antagonist (Fig 
2.5A) (May and Wightman 1989a; Benoit-Marand et al 2007; Moquin and Michael 2009). 
Further, this result is consistent with reports implicating local D2R activation in evoked DA 
autoinhibition (Herr et al 2010).   
 
3.4.3 Picospritzer leak alters evoked dopamine 
In order to determine if the picospritzer leaks a physiologically relevant concentration of analyte 
the prior experiment was repeated sans the picospritzer ejection. A picospritzer electrode with 
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raclopride in the tip solution was lowered into a new striatal location and a 3 s stimulation 
evoked dopamine release. After 5 minutes the stimulation was repeated. At no point in the 
experiment was raclopride delivered into the extracellular space by a picospritzer ejection.  
The second stimulus evoked a larger magnitude of dopamine, consistent with the profile 
of evoked release from uninhibited terminals (Fig 3.2D). The change in evoked dopamine is 
statistically identical to the change caused by the picospritzer ejection of raclopride (Fig 3.2E). 
These results clearly demonstrate that a physiologically relevant concentration of raclopride 
leaked from the picospritzer tip within 5 minutes, blocking D2R mediated autoinhibition (see 
figure legend of ANOVA details).  
 
3.4.4 Segmented flow  
In order to gain temporal control of analyte delivery, the analyte solution was separated from the 
tip solution by a segment of air (Fig 3A). While the tip solution still leaked, the air segment 
prevented the analyte from reaching the tip and leaking into the extracellular space. Picospritzer 
ejections compress the air bubble, allowing the analyte solution to mix into the tip solution (Fig 
3B). After several ejections, the tip solution was primed with a high concentration of analyte (Fig 
3C). Further picospritzer ejections delivered the analyte into the extracellular space. 
Note that the air bubble remains in place in the picospritzer barrel and is not ejected into 
the brain. This is important because ejecting air onto the electrode surface breaks the 
electrochemical connection. 
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Figure 3.2 The picospritzer tip leaks.  
(A) Averaged in vivo baseline recordings from single barrel carbon fiber electrodes and double barrel picospritzer 
electrodes containing an aCSF solution (n = 3). Standard deviations at 1 second intervals are plotted (vertical bars). 
Standard deviations less than 0.1 µM were not plotted for clarity. The baseline signal from a single barrel electrode 
is stable. The picospritzer electrode baseline is not stable. (B-C) 3 s evoked DA profiles five minutes before and 30 s 
after a picospritzer ejections. Circles and triangles represent the start and end of stimulation respectively. (B) 
Exogenous DA did not alter the profile of evoked release. (C) Locally delivered raclopride removed autoinhibition, 
consistent with its function as a D2R antagonist. (D) Raclopride alters the evoked response profile even if a 
picospritzer ejection is not performed. The picospritzer electrode containing raclopride is lowered into a new 
recording location immediately followed by a 3 s stimulation (black line). After five minutes the 3 s stimulation is 
repeated (grey dashed line).  (E) The normalized change in maximum evoked amplitude of ejected and non-ejected 
(i.e. leaked) raclopride are nearly identical and statistically different than the effect of exogenous dopamine (n=3, 
one-way ANOVA, tukey post-hoc, F(5,12)= 31.4, † p < 0.001).  
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Figure 3.3 Schematic of a picospritzer electrode utilizing segmented flow.  
(A) The picospritzer barrel was filled with two separate solutions; an aCSF solution (grey) at the tip, and an analyte 
solution (grey with black squares) backfilled into the barrel. An air buble (~1mm in length) separated the two 
solutions.  (B) Air pressure from the Picospritzer compresses the air bubble allowing the analyte solution to mix 
with the aCSF solution. (C) Following several ejections the tip solution is loaded with the analyte. Further 
picospritzer ejections will deliver the analyte along with aCSF.  
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3.4.5 Temporal control of picospritzer ejections 
A solution of aCSF was front filled into the picospritzer tip via capillary action. An analyte 
solution of DA and aCSF was backfilled into the picospritzer barrel, leaving an air bubble to 
segment the two solutions. The electrode was placed in a beaker of PBS. Using fast scan cyclic 
voltammetry, the carbon fiber electrode monitored changes in current during a series of 
picospritzer ejections (30 psi, 0.5 s). The change in current over time is plotted at two potentials 
in each experiment; a non-DA redox potential (Fig 3.4A), and DA’s maximum oxidation 
potential (Fig 3.4B). The start of each picospritzer ejection is marked by a black circle.  
Differences in ionic concentrations of the aCSF solution in the barrel and the PBS 
solution in the beaker generate a change in current at the electrode surface during all picospritzer 
ejections (Fig 3.4A). Every picospritzer ejection caused a similar increase in current at the non-
DA redox potential, indicating that each picospritzer ejection expels a similar amount of solution 
into the beaker. These current changes did not occur at DA’s oxidation or reduction potential, 
and thus are not associated with the delivery of DA into the beaker.  
At the DA oxidative potential (~650 mV) the current did not increase during the first 
three ejections (Fig 3.4B). As a change in the non-DA redox potential was recorded, initial 
picospritzer ejections deliver aCSF, but not DA, into the beaker. DA is detected during latter 
picospritzer ejections (Fig 3.4B). The DA oxidation current continues to rise with each ejection, 
demonstrating that the DA solution continues to mix into the tip solution increasing the DA 
concentration at the tip.  
Background subtracted cyclic voltammograms from the 2nd and 6th picospritzer ejections 
confirm that DA is delivered during the latter, but not initial, ejections (Fig 3.4C and D).  While 
there are notable fluctuations in the background subtracted voltammotram at the 2nd ejection, the 
voltammogram lacks discernable DA oxidation or reduction peaks (Fig 3.4C). These current 
58 
 
changes are associated with differences in the ionic concentrations of the two buffer solutions. 
The background subtracted cyclic voltammogram from the 6th ejection has prominent DA 
oxidation and DA-o-quinone reduction peaks (Fig 3.4D). These data indicate that several 
picospritzer ejections are required to load DA into the tip solution. Prior to mixing DA is 
separated from the tip solution, and thus not ejectable. It should also be noted that the 6th cyclic 
voltammogram also contains the characteristic features associated with the ejection of aCSF into 
PBS. Note the peak at 250 mV during the forward sweep and the rise in current during the 
potential return from -500 to 0 mV. These features can be removed by background subtracting 
the 2nd voltammogram from the 6th. 
These results are reproducible across several different electrodes (Fig 3.4E). All 
electrodes utilizing segmented flow require several Picospritzer ejections before the analyte 
reaches the picospritzer tip solution (see figure legend of ANOVA details). The DA oxidation 
current consistently increases during continued ejections as the concentrated DA solution 
continues to mix into the tip solution. The DA current levels off as the concentration of DA in 
the tip solution approached the analyte solution concentration (data not shown).  
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Figure 3.4 Controlled drug release from the picospritzer using segmented flow.  
A picospritzer electrode containing a solution of aCSF and DA is placed into a beaker of PBS. (A) The current 
change at an aCSF/PBS-sensitive, DA-insensitive potential (250 mV in this example) verify ejections of aCSF 
solution into the beaker during each picospritzer event (circles). (B) Current change at DA’s oxidative potential 
show that DA was not in the aCSF solution ejected during the first three picospritzer events, but did mix into the tip 
solution during latter ejections. (C, D) Cyclic voltammograms recorded during the 2nd and 6th picospritzer ejection 
respectively. The 2nd voltammogram has a noticeable peak at 250 mV (due to differences in the PBS and aCSF 
solution), but does not have any discernable DA oxidation or reduction peak. The 6th voltammogram has classic DA 
redox peaks. Notice that the aCSF/PBS peak at 250 mV remains. (E) The delayed release of DA from a picospritzer 
utilizing segmented flow is reproducible (n=3, one-way ANOVA, tukey post-hoc, F(5,12)= 98.9, *,†.‡ p < 0.001).  
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3.4.6 Segmented flow in vivo 
In vivo, temporal control of analyte delivery is obtained using the picospritzer electrode and 
segmented flow. In this example the tip was filled with aCSF and the barrel was backfilled with 
an aCSF solution containing DA. The two solutions were separated by an air bubble. The 
picospritzer electrode was place in the striatum of an anesthetized rat and the DA oxidation 
current was monitored during picospritzer ejections (20 psi, 0.5 s).  
A current change at the DA oxidation potential is noticed from the first picospritzer 
ejection (Fig 5). However, cyclic voltammograms recorded during these ejections did not have 
discernable DA oxidation or reduction peaks (Fig 5 inset). Thus, this current increase is 
associated with differences in the ionic concentration of the extracellular space and aCSF 
solution and not with the ejection of DA.  
Several picospritzer ejections are required to expel DA into the extracellular space (Fig 
5). This result demonstrates that segmented flow works in vivo. In this case, electrode post-
calibration revealed that an extremely large DA concentration (~ 100 µM) was ejected into the 
striatum. This increase in concentration is quite large compared to physiological fluctuations in 
DA concentration (Garris et al 1994; Benoit-Marand et al 2001; Phillips et al 2003b; Robinson 
et al 2003; Heien et al 2005). The concentration of DA, the ejection time, and ejection pressure 
can be adjusted in order to deliver smaller, physiologically relevant concentrations of DA.  
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Figure 3.5 Segmented flow controls DA release in vivo.   
Current change at DA’s oxidative potential show that several picospritzer ejections (circles) are required to load DA 
into the tip solution before it can be ejected into the extracellular space. There is an increase in current during each 
picospritzer ejection at this potential. However, a cyclic voltammogram from the first ejection (inset) shows that this 
increase does not correspond to DA.  
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3.5 DISCUSSION 
 
In this study we discover that the tip of picospritzer leaks buffer solution and analytes.  This 
issue was discovered during the implementation of a dual function picospritzer electrode device 
capable of delivering analytes of interest and electrochemical detection in the same location. This 
device places the detection electrode at the site of analyte delivery, which allows for electrode 
optimization, and minimizes diffusional distortion of the analyte. This issue was previously not 
identified because other experimental setups place the detection electrode 100 to 300 µm away 
from the picospritzer tip (Cass et al 1993; Cragg et al 2001; Daws and Toney 2007; Makos et al 
2009).  
 The uncontrolled release of analyte into the extracellular space is resolved using 
segmented flow. The analyte solution is separated from the tip solution with an air bubble. Initial 
picospritzer ejections compress the air bubble separating the two solutions allowing the analyte 
to mix into the tip solution. Once in the tip solution the analyte is delivered during further 
picospritzer ejections. While segmented flow does not prevent the picospritzer tip from leaking, 
it does control the time course of analyte delivery.  
 
3.5.1 Qualifying the picospritzer leak 
In this study we demonstrate picospritzer tip leakage two ways. First we monitor in vivo baseline 
signals from signal barrel electrodes and double barrel picospritzer electrodes filled with aCSF 
(Fig 3.2A). The baseline signal from the picospritzer electrode is clearly less stable than the 
single barrel electrode. The baseline signal instability of the picospritzer electrode indicates that 
either the electrode or the extracellular environment is not stable. Single barrel electrodes in both 
this and other experiments have stable baselines on the minute time scale (Sabeti et al 2002; 
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Borland and Michael 2004; Wang et al 2010). The stability of the single barrel electrode 
indicates that both the electrode surface and the ionic concentration of the extracellular fluid are 
constant during the experimental procedure. Figure 3.5 demonstrates that the aCSF solution, 
while an accurate mimic of extracellular brain fluid, is not an exact match. Picospritzer ejections 
of aCSF in vivo create a large current change due to variations in the ionic concentration of the 
two solutions. Thus, the unstable baseline detected by the picospritzer electrode appears to be an 
artifact of aCSF solution leaking from the tip.  
 The second way we detect leaking from the picospritzer tip is through the actions of the 
D2R antagonist raclopride.  The D2R is an autoinhibitory receptor that suppresses DA release 
upon activation (Garris et al 1993; Benoit-Marand et al 2001; Kita et al 2007; Moquin and 
Michael 2009). Systemic intraperitoneal injections of raclopride block D2R function, removing 
the delayed onset of evoked release in slow domains (Fig 2.5A)(Moquin and Michael 2009) and 
the short term depression of evoked release in hybrid responses (Fig 4.1C) (Moquin and Michael 
2011).  These results are reproducible when raclopride is locally administered via picospritzer 
ejections (Fig 3.2C) or iontophoresis (Herr et al 2008), implicating pre-synaptic D2Rs in 
autoinhibition. The effect of raclopride on evoked DA is identical even when raclopride is not 
ejected from the picospritzer tip (Fig 3.2D). This result demonstrates that a physiologically 
relevant concentration of raclopride leaks from the electrode tip, blocking D2R activity. Thus the 
picospritzer does not have temporal control of analyte release, making the assessment of the 
effects of drugs on the dopamine system impossible.  
 
3.5.2 Controlling analyte release with segmented flow 
Figure 3.3 schematically describes how segmented flow controls the time course of analyte 
reaching the picospritzer tip. Briefly, the analyte is separated from the tip solution by an air 
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bubble. The picospritzer tip still leaks, but the analyte is not in the tip solution so only aCSF 
buffer enters the extracellular space. The ejection of aCSF does not change the profile of evoked 
DA release (Fig 3.2B). Also, aCSF does not change the DA clearance rate in slow domains 
(Moquin and Michael 2011).  In fact the clearance rate of evoked DA and exogenous DA is 
identical in slow domains (Fig 4.2E). Thus, aCSF leaking does not alter the function of DA 
neurons.  
Cyclic voltammograms recorded during initial picospritzer ejection confirm that the 
analyte, DA in this example, is not in the tip solution (Fig 3.4B and 3.5). These initial ejections 
also serve to compress the air bubble separating the two solutions. The ejection of analyte into 
the extracellular space during latter ejections confirms that the compressed air bubble allows the 
analyte solution to mix into the tip solution (Fig 3.4B and 3.5).   
The addition of segmented flow allows the picospritzer electrode to temporally control 
analyte release, adding a new tool to the in vivo study of dopaminergic activity. Previously, 
experimental designs were limited by the inability to move both the picospritzer tip and detection 
electrode while maintaining the same distance of separation (Sabeti et al 2002; Wang et al 2010). 
This limitation made local administration of both permeable and non-permeable analytes 
following electrode optimization near impossible. Optimization increases the distance between 
the electrode and picospritzer tip, which in turn magnifies spherical diffusion. If the electrode is 
optimized then only permeable analytes can be administered by intraperitoneal or intravenous 
injections. The double barrel picospritzer electrode moves both components in tandem so 
distance between the electrode and picospritzer tip remains the same during electrode 
optimization. Further, segmented flow prevents the analyte from reaching the tip during 
optimization. Thus this device can be optimized into the desired DA domain, the pre-drug 
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response recorded, the analyte delivered into local environment, and the analyte effect on the 
local DA system measured.  
 
3.5.3 Diffusion 
Experimental setups using separate analyte delivery and detection electrode devices leave a 100 
to 300 µm gap between the two devices (Cass et al 1993; Cragg et al 2001; Sabeti et al 2002; 
Daws and Toney 2007; Wang et al 2010). At this distance analytes reach the electrode via 
diffusion. Diffusionally distorted signals are initially delayed, then accelerate, and overshoot 
after the end of analyte delivery (Engstrom et al 1988; Sabeti et al 2002). Diffusional distortion 
also limits the amount of analyte that reaches the detection electrode. Analytes ejected from a 
point source diffuses spherically into the surrounding tissue, exponentially decreasing in 
concentration (Bard and Faulkner 2001). In order to obtain a specific concentration of analyte 
some distance away from the point source, a significantly larger concentration is required at the 
source. In the above example a 200 µM concentration was delivered into the extracellular space 
200 to 300 µm away from the detection electrode in order to obtain a 1 µM DA concentration at 
the electrode surface (Sabeti et al 2002).  The effects of this supra-physiological concentration of 
DA could alter the surrounding tissue, changing DA terminal function.  
The placement of the picospritzer tip at the site of the detection electrode limits diffusion 
such that DA is immediately detectable at the onset of the picospritzer ejection (Fig 3.5). The DA 
response is both rapid and linear without acceleration or overshoot. Because there is limited 
diffusion, the analyte concentration detected at the site of the electrode approximates the 
concentration of analyte ejected. Therefore, physiologically relevant concentrations of analyte 
and smaller volumes of buffer solution are delivered into the extracellular space. 
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Spherical diffusion limits the distance analytes migrate from the tip (Bard and Faulkner 
2001). Low concentrations of analytes ejected or leaked from the picospritzer tip will not reach 
the detection electrode at a detectable concentration. For this reason experiments placing the 
analyte delivery and detection electrode apart from each other were unable to detect the leak 
(Cass et al 1993; Sabeti et al 2002; Borland and Michael 2004; Wang et al 2010). Once the 
picospritzer electrode and tip are adjacent, the leak and its physiological impact become obvious 
(Fig 3.2). Spherical diffusion of an analyte prevents physiologically significant concentrations of 
analyte reaching the extracellular space around a detection electrode that is outside of the leak’s 
spherical diffusion radius. Therefore, the leak is not directly impacting the DA neurons in 
experimental setups that separate the two devices. Thus, the electrodes in these experiments are 
sampling from initially unaltered tissues (Cass et al 1993; Cragg et al 2001; Sabeti et al 2002; 
Borland and Michael 2004; Daws and Toney 2007; Wang et al 2010).  
 
3.5.4 Background subtraction 
The ionic concentration of aCSF and the extracellular fluid are not identical. Ejection of aCSF 
into the extracellular space at the site of the detection electrode changes the ionic concentration, 
altering the redox current (Fig 3.2C and 3.5). These current changes are different in each 
experiment and can occur at dopamine’s oxidation potential (Fig 3.5). Thus, current changes at 
650 mV may not be due solely to an increase in the DA concentration (Fig 3.5 inset). As non-DA 
current increases occur during each picospritzer ejection (Fig 3.2A), they also occur during the 
ejection of DA. Therefore, changes in amplitude during a picospritzer ejection are a product of 
DA oxidation and ionic concentration differences between the buffer solutions. The non-DA 
current changes can be removed by subtracting cyclic voltammograms during the initial 
picospritzer ejections (aCSF only) from cyclic voltammograms during DA ejection (aCSF and 
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DA) (Fig 3.2C and D). This background subtraction method allows for an accurate measurement 
of DA delivered during each picospritzer ejection.  
 
3.5.5 Failed devise designs 
We attempted several other methods to prevent picospritzer tip leakage and gain temporal 
control of analyte release. In one set of experiments oil was substituted for the air bubble as a 
means to separate the tip and analyte solutions. Because oil is not compressible, the tip and 
analyte solutions did not mix during picospritzer ejections. So the analyte was never in an 
ejectable state. Further, the oil did not prevent leaking.  
Smaller diameter picospritzer tips were pulled to minimize leakage. The tighter tips 
required higher pressures (>30 psi) to eject solution into the extracellular space. Following these 
high pressure ejections evoked DA responses were suppressed or disappeared altogether, 
suggesting that the ejection damaged the local terminal field. This result is not surprising as high 
pressure picospritzer ejections are used to create fluid percussion injuries, a traumatic brain 
injury model (Thompson et al 2005; Frey et al 2009). Note that low pressure picospritzer 
ejections of solution did not alter evoked DA response (Fig 3.2B). 
In another design, the analyte solution was backfilled into the picospritzer leaving a 
pocket of air at the picospritzer tip. This setup prevented both analyte and aCSF leakage. The 
initial picospritzer ejection moved the analyte solution to the tip, delivering air into the 
extracellular space. Latter ejections deliver the analyte. Similar to high pressure liquid ejections, 
evoked DA responses following the initial air ejection were suppressed or undetectable 
compared to pre-ejection responses, suggesting that the air bubble damaged the neuron.   
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3.5.6 Segmented flow and leaking 
Segmented flow gains temporal control over the release of analytes into the extracellular space. 
However, this design does not prevent picospritzer leakage, as the baseline signal is still very 
unstable (Fig 3.5). Therefore, once the analyte is in the tip solution it is free to leak into the 
extracellular space. As the concentration of analyte leaked can be physiologically relevant, this 
method cannot be used to deliver multiple doses of analyte and varying concentrations. Despite 
this limitation the picospritzer electrode can still be used to assess changes in neuronal activity 
before and after the local administration of analytes.  
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4.0 AN INVERSE CORRELATION BETWEEN APPARENT RATE OF DOPAMINE 
CLEARANCE AND TONIC AUTOINHIBITION IN SUBDOMAINS OF THE RAT 
STRIATUM: A POSSIBLE ROLE OF TRANSPORTER-MEDIATED DOPAMINE 
EFFLUX 
 
4.1 ABSTRACT 
 
The dopaminergic terminal field in the rat striatum is compartmentalized into sub-domains that 
exhibit distinct dynamics of electrically evoked dopamine release.  The fast striatal domains, 
where dopamine release is predominantly vesicular, exhibit conventional dopaminergic activity.  
However, vesicular dopamine release is tonically autoinhibited in the slow domains, which 
suggests that dopamine reaches the autoreceptors via a non-vesicular route.  Hence, it appears 
that the domains use distinct mechanisms to regulate the basal dopamine concentration available 
to activate, or not, presynaptic autoinhibitory receptors.  However, direct detection of local 
variations in tonic extracellular dopamine concentrations is not yet possible.  So, the present 
study employed voltammetry to test the hypothesis that the apparent rate of dopamine clearance 
from the extracellular space should be domain-dependent.  The apparent rate of dopamine 
clearance is equal to the difference in the rates of dopamine release and uptake that determine 
extracellular dopamine concentrations.   This study confirms that the apparent rate of dopamine 
clearance is slower in the slow striatal domains where vesicular dopamine release is tonically 
autoinhibited.  These findings support the view that the basal concentration in slow domains is 
maintained by a non-vesicular release process, possibly transporter-mediated efflux. 
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4.2 INTRODUCTION 
 
The dopamine (DA) transporter (DAT), a chloride-dependent member of the SLC6 family of 
neurotransmitter:sodium symporters, intimately contributes to the regulation of extracellular DA 
concentrations in the brain (Iversen 1971; Amara and Kuhar 1993).  Understanding DAT 
function is significant because it is targeted by a variety of antidepressant and psychoactive drugs 
(Torres et al 2003; Mandt and Zahniser 2010).  Prior studies have established that DAT function 
is dynamically regulated by protein trafficking, interactions with the DA D2 receptor (D2R), 
protein-lipid interactions, membrane voltage, and ligand and substrate binding (Ingram et al 
2002).  DAT’s primary function appears to be reuptake of DA from the extracellular space, but it 
also releases DA in the presence of exogenous DA-releasers, such as amphetamine (Sulzer et al 
1993).  The present study, however, contributes to an emerging body of evidence suggesting that 
the DAT may also release DA in the absence of amphetamine-like drugs. 
In vitro studies have demonstrated that striatal terminals release DA via DAT-mediated 
DA efflux (DDE) (Cheramy et al 1986; Lonart and Zigmond 1991; Leviel 2001).  In vivo studies 
likewise suggest that DDE is functionally relevant within certain specific subdomains of the rat 
striatum (Moquin and Michael 2009; Wang et al 2010).  Voltammetric recordings show that the 
striatum is compartmentalized into spatial domains that yield distinct fast-type and slow-type 
responses during electrical stimulation of midbrain DA axons.  An autoinhibitory tone on DA 
terminals contributes to determining whether a given recording site corresponds to a fast or slow 
domain.  The autoinhibitory tone is minimal in fast domains (Garris et al 1993; Benoit-Marand et 
al 2001) but intense in slow domains (Moquin and Michael 2009; Wang et al 2010), which 
suggests that the domains operate under different basal DA concentrations.  Since electrically 
evoked DA release, a vesicular event, is autoinhibited in the slow domains, it appears that the 
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DA responsible for the autoinhibition reaches the extracellular space via a non-vesicular route.  
This concept is supported by the finding that the striatum contains a tonic pool of extracellular 
DA that is both tetrodotoxin-insensitive and nomifensine-sensitive (Borland and Michael 2004), 
which are classic hall-marks of DDE. 
This emerging evidence that DDE has a functional role in the striatum is at odds with a 
considerable body of literature.  According to microdialysis, for example, DA release is 
exclusively vesicular (Westerink et al 1987; Santiago and Westerink 1990) except in the 
presence of DA releasers (Carboni et al 1989; Schmitz et al 2001).  However, microdialysis is an 
averaging technique (Bungay et al 2007) that does not detect spatially localized concentration 
differences.  At present, no technology has the demonstrated ability to directly detect localized 
variations of basal extracellular DA concentrations.  For this reason, the present study was 
designed to examine this issue via an alternate route.   
We tested the hypothesis that the fast and slow striatal domains should exhibit distinct 
values of the apparent rate of DA clearance, Vapp, a quantity that depends on the rates of DA 
uptake and release that determine the extracellular DA concentration (Chen 2005; Michael et al 
2005; Dreyer et al 2010).  We used voltammetry to quantify Vapp in vivo after electrically 
evoking the release of endogenous DA (Wu et al 2001) and after ejecting exogenous DA from a 
pipet (Cass et al 1993; Kiyatkin et al 2000; Sabeti et al 2002).  Our findings confirm that the rat 
striatum exhibits the hypothesized regional variation in Vapp and, as expected, that Vapp is 
significantly slower in those striatal domains where extracellular dopamine concentrations 
appear to be sufficiently high to tonically autoinhibit vesicular DA release.  
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4.3 METHODS AND MATERIALS 
 
4.3.1 Carbon fiber microelectrodes 
Electrodes were constructed by inserting 5-μm diameter carbon fibers (T650, Cytec Carbon 
Fibers LLC., Piedmont, SC) into single barrel borosilicate glass capillaries (0.4 mm ID, 0.6 mm 
OD, A-M systems Inc., Sequim, WA), pulling the capillaries to a fine tip with a vertical 
micropipette puller (Narishige, Los Angeles, CA), backfilling the tubes with a low-viscosity 
epoxy (Spurr Epoxy, Polysciences Inc., Warrington, PA), and connecting the fiber to a hook-up 
wire with a droplet of mercury.  The exposed fibers were cut to 400 μm and sonicated in reagent-
grade isopropyl alcohol (Sigma, St. Louis, MO) containing activated carbon (Fisher Scientific, 
Fair Lawn, NJ) for 30 minutes (Bath et al 2000). 
 
4.3.2 Fast scan cyclic voltammetry 
Voltammetric recording was performed by fast scan cyclic voltammetry using an EI 400 high-
speed potentiostat (originally constructed by Ensman Instruments but presently available from 
ESA Inc., Chelmsford, MA) and the “CV Tar Heels v4.3” software package (courtesy of Dr. 
Michael Heien, present address Department of Chemistry, University of Arizona, Tucson AZ, 
USA).  The rest potential was 0 V vs Ag/AgCl and the voltammetric waveform consisted of 
three linear potential sweeps to +1 V, -0.5 V, and back to 0 V at a sweep rate of 400 V/s. The 
scans were repeated at 10 Hz.  The DA oxidation current was recorded between 0.5 and 0.7 V 
during the first sweep.  DA voltammograms were obtained by background subtraction.    
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4.3.3 Animals 
Male Sprague-Dawley rats (250-350g) (Hilltop, Scottsdale, PA) anesthetized with isoflurane (2% 
by vol.) and placed in a stereotax (David Kopf Instruments, Tujunga, CA) with the incisor bar 
raised 5 mm above the interaural line (Pellegrino et al 1979).  A heating blanket (Harvard 
Apparatus, Holliston, MA) maintained body temperature at 37oC.  A twisted, bipolar, stainless 
steel stimulating electrode was placed over the medial forebrain bundle (from bregma: 1.6 mm 
lateral, 2.2 mm posterior, 8.0 mm below dura) (Pellegrino et al 1979).  A carbon fiber 
microelectrode was placed in the ipsilateral striatum (from bregma: 2.5 mm lateral, 2.5 mm 
anterior, initially 4.5 mm below dura) (Pellegrino et al 1979).  The final position of the 
stimulating electrode was determined by lowering it until evoked DA release was observed in the 
striatum: this is a well-established protocol for identifying effective midbrain stimulus sites 
(Ewing et al 1983; Kuhr et al 1984; Heien et al 2005). As appropriate, the striatal recording 
location was optimized to permit detection of hybrid evoked responses (explained further in the 
Results section): the optimization procedure involved lowering the carbon fiber electrode deeper 
into the striatum until a hybrid stimulus response was observed.  
 
4.3.4 Stimulation 
Electrical stimulation was delivered as an optically isolated, constant-current, biphasic waveform 
(frequency 60 Hz, pulse height 270 µA, pulse width 2 ms).  The stimulus duration was 200 ms 
(12 pulses) during experiments involving fast-type responses, 3 s during experiments involving 
slow-type responses, and 3-5 s during experiments involving hybrid responses.     
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4.3.5 Picospritzer system 
Pressure-ejection of exogenous substances (raclopride and dopamine) into the extracellular space 
of the striatum was by means of a double-barreled micropipet: one barrel contained a carbon 
fiber microelectrode and the other was used for pressure-ejection (Fig 3.1).  The open barrel was 
pre-loaded with either 25 mM DA or 2 mM raclopride dissolved in artificial cerebral spinal fluid 
(1.2mM Ca2+, 152mM Cl-, 2.7mM K+, 1.0mM Mg2+, 145mM Na+, pH 7.4).  The solution was 
pressure ejected (~20 psi) with a Picospritzer III (Parker Hannifin, Fairfield, NY).  In the case of 
experiments involving exogenous DA, the ejection time was adjusted between 0.1 and 0.5 s so 
that the amplitude of the voltammetric response to exogenous DA matched the amplitude of the 
electrically evoked response at the same recording location (see Results section for further 
details).  In the case of experiments involving the pressure-ejection of raclopride, the ejection 
lasted for 2 s and occurred 5 min prior to the next electrical stimulus.  
 
4.3.6 Electrode calibration 
Microelectrode DA calibration was performed after the microelectrodes were removed from 
brain tissues and mounted into a gravity-fed flow-through cell.  Conversion of in vivo oxidation 
currents to DA concentrations was based on post-calibration results. Standard solutions were 
prepared by dissolving DA in artificial cerebrospinal fluid. 
 
4.3.7 Drugs 
Drugs were dissolved in phosphate buffered saline (155mM Na+, 155mM Cl-, 100mM 
phosphate, pH 7.4).  Nomifensine maleate (Sigma Aldrich, St. Louis, MO) was administered at a 
dose of 20 mg/kg i.p.  Raclopride tartrate (Sigma Aldrich, St. Louis, MO) was administered at a 
dose of 2 mg/kg i.p.  
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4.3.8 Modeling and statistics 
DA clearance profiles were constructed as follows: The time of the first voltammetric 
measurement after the termination of an electrical stimulus or pressure ejection was defined as 
t = 0 (x-axis).  The time required for the completion of DA clearance after electrical stimulation 
or pressure ejection was identified by using an Excel spreadsheet to determine the linear 
regression slope of sequential 5-point line segments on the clearance profile.  The midpoint of 
the first line segment with a slope below -0.1μM/s was taken as a measure of a) the extracellular 
lifetime of DA and b) the zero-point of the change in DA concentration (y-axis): this procedure 
eliminated contributions from occasional small baseline shifts that occurred between the onset of 
the stimulus and the completion of DA clearance.   
The DA clearance profiles for each group were averaged together (n=4) and compared using 
two-way ANOVA (1st factor – group; 2nd factor – time point) and a Tukey post hoc test. 
Extracellular DA lifetimes were averaged together (n=4 per group) and compared using one-way 
ANOVA and a Tukey post hoc test.  Throughout this study, the intensity of the stimulus was 
sufficient to cause the initial segment of the clearance profile to be linear (r2>0.96): the initial 
linear clearance rates were averaged (n=4 per group) and compared using one-way ANOVA and 
a Tukey post hoc test.  In all figures, the error bars indicate s.e.m.  
 
4.4 RESULTS  
 
4.4.1 Voltammetric identification of fast and slow DA domains 
Voltammetric recordings of electrically evoked DA release in the rat striatum yield distinct 
responses, classified as fast-type and slow-type according to previously explained criteria 
(Moquin and Michael 2009).  The slow-type responses are characterized by a delay in the onset 
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of evoked release when the stimulus begins and short-term facilitation of release with continued 
stimulation (Fig 4.1A).  Systemic administration of raclopride, a selective D2-antagonist, 
abolishes the delay in the onset of evoked release (Fig 4.1A), confirming that the slow-type 
response is a consequence of an autoinhibitory tone on DA terminals.  This tone is established 
prior to the onset of the stimulus, indicating that it derives from non-evoked DA release.  
The position of the voltammetric electrode can be optimized to locate recording sites that 
yield hybrid responses (Fig 4.1B) with a fast-type initial component and a subsequent slow-type 
component.  The fast-type responses are characterized by evoked release that starts without delay 
and then exhibits short-term depression, which sometimes produces a ‘dip’ between the fast and 
slow components of the hybrid response (Fig 4.1B).  The short-term depression is attributable to 
the rapid onset of autoinhibition caused by the evoked DA release (Dugast et al 1997; Benoit-
Marand et al 2001; Phillips et al 2002).   The initial component sometimes appears as a leading 
shoulder on the response (Fig 4.1C), rather than a stand-alone peak (Fig 4.1B), because different 
hybrid sites have different fast and slow contributions.  Pressure-ejection of raclopride from a 
pipet adjacent to the microelectrode (Fig 3.1) had no effect on the amplitude of the initial fast 
component but significantly increased the amplitude of the subsequent slow component (Fig 
4.1C and 2d: see figure legend for ANOVA results).  Because the fast component was refractory 
to raclopride, it appears to derive from DA terminals that are not autoinhibited prior to the 
stimulus.  This finding is consistent with previous reports of fast evoked signals refractory to 
D2R antagonists (Garris et al 1994).  These results, which show that autoinhibitory D2Rs are 
present and functional in both fast and slow domains, point to the tonic DA concentration present 
in the extracellular space prior to the stimulus as a principle determinant of the autoinhibitory 
tone. 
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Figure 4.1 Fast and slow domains revealed by voltammetric recordings of evoked DA release.   
(A) In slow domains, evoked DA release is delayed and exhibits facilitation as the stimulus proceeds.  Raclopride (2 
mg/kg i.p.) abolishes the delay, confirming the role of autoinhibition. (B) When the recording electrode straddles 
both fast and slow domains, hybrid responses are obtained.  The initial component exhibits no delay in evoked 
release: a robust DA signal is detected on the first voltammetric measurement, which occurs 100 ms after the onset 
of the stimulus.  The initial component exhibits depression as the stimulus continues, which is attributable to the 
onset of autoinhibition in the fast domain caused by the evoked rise in DA concentration.  The fast component is 
isolated by limiting the stimulus duration to 200 ms (gray line). (C) Local picospritzer ejections of raclopride 
confirm the role of autoinhibition on the hybrid-type responses curve profile. (D) In hybrid-type responses, 
raclopride did not alter the initial amplitude of evoked DA following the first 0.2s of stimulation (n=4, One-way 
ANOVA, F(1,6)=0.202, p=0.67), but significantly increased the amplitude following 3s of stimulation (n=4, One-way 
ANOVA, F(1,6)=353.1, † p<0.0001). 
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4.4.2 Apparent DA clearance rates in fast and slow striatal domains  
During the remainder of this study, fast-type responses were obtained by optimizing the 
electrode position to find hybrid sites and then shortening the stimulus to 200 ms (12 pulses).  
The difference between Vapp within fast and slow domains of the striatum of an individual rat is 
readily apparent even from the illustrative responses in Fig 4.2A.  DA was cleared from the fast 
domain within 0.5 s, whereas clearance from the slow domain required more than 2 s.  To obtain 
Fig 4.2A, the duration of the stimuli was adjusted to obtain similar response amplitudes at the 
two recording sites: the time needed to clear the same DA concentration from each site is 
obviously different.  The remainder of this study is devoted to a quantitative evaluation of the 
DA clearance profiles in fast and slow striatal domains.   
The clearance profiles obtained in fast and slow domains are significantly different (Fig 
4.2B, see figure legends for ANOVA results).  The clearance profiles in slow domains persist for 
a longer duration and exhibit a slower initial slope.  Fig 4.2C reproduces the data of Fig 4.2B but, 
for clarity, omits the error bars and includes the linear regression lines that best fit the initial 
linear segment of each clearance profile.  In generating Fig 4.2C, responses were only included 
in the data set if at least three data points on the descending phase of the response produced a 
straight line with r2>0.96.   All slow-type clearance profiles met this criterion, whereas only 4 of 
the 7 fast-type profiles did so.  At the other 3 fast sites, DA returned to baseline within 200 ms 
and was thus too fast to quantify by our method.  It is likely that omitting these ‘very fast’ 
profiles leads to an underestimate of the apparent clearance rate in fast domains.  Nevertheless, 
the initial clearance slope (Fig 4.2D) in fast and slow domains, 4.8 ± 1.2 μM/s and 1.4 ± 0.46 
μM/s, respectively, are significantly different (see the figure legend for ANOVA details).   
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Figure 4.2 Fast-type and slow-type responses in the rat striatum.  
(A) Evoked responses (stimulus start - circle, stimulus end –triangles) from two recording sites in one rat. Fast-type 
responses exhibit immediate DA release when the stimulus begins.  Due to autoinhibition, slow-type responses 
exhibit a delayed onset of evoked release and short-term facilitation. (B) Fast- and slow-type responses exhibit 
differential apparent DA clearance rates (n=4, Two-way ANOVA, F(1,180)=118.9, † p<0.00001). (C) Linear 
regression lines fit to the averaged clearance curves in panal (B) exhibit distinct slopes. (D) The clearance slopes 
observed in fast and slow domains are significantly different (n=4, One-way ANOVA, F(1,6)=6.93, † p=0.039), with 
slow domains exhibiting the slower apparent rate of DA clearance.  (E) Slow-type apparent DA clearance is 
identical to the apparent clearance of exogenous DA and is DAT-dependent (nomifensine-sensitive) (n=4, Two-way 
ANOVA – Tukey post-hoc, F(2,270)=56.18, † p<0.00001). (F) The extracellular lifetime of DA in fast and slow 
domains is significantly different; in slow domains, the lifetime of DA is identical to the lifetime of exogenous DA 
and is DAT-dependent (n=4, One-way ANOVA – Tukey post-hoc, F(3,12)=20.70, †‡ p=0.00005). 
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We compared DA clearance profiles obtained from evoked responses in slow domains with 
those obtained after pressure ejection in the same recording location.  We adjusted the duration 
of the pressure ejection so that the initial amplitude of the profiles obtained after evoked release 
and pressure ejection were similar.  The clearance profiles after evoked release and pressure 
ejection are essentially identical (Fig 4.2E).  The evoked responses in slow domains are sensitive 
to the DAT-inhibitor, nomifensine, which confirms the DAT is active within slow domains (Fig 
4.2E).  The extracellular DA lifetime (Fig 4.2F) is shortest after fast-type evoked release (0.8 s).  
The lifetime is longer after slow-type evoked release (2.1 s), similar to that observed after 
pressure-ejection (2.3 s), and further extended after nomifensine administration (3.7 s). 
 
4.4.3 Effect of evoked DA concentration on clearance 
The clearance profiles of Fig 4.2C are re-plotted in Fig 4.3A normalized with respect to the 
initial DA amplitude.  The normalized initial clearance slopes in the two domains are 
significantly different (Fig 4.3B), which further confirms that the difference in slope is not 
dependent on the initial DA amplitude.  The regression lines that give the best fit to the initial 
linear segments of the clearance profiles from 8 individual experiments, 4 from fast domains and 
4 from slow domains (Fig 4.3C), allow examination of the time at which the regression lines 
intersect the x-axis (i.e. the time at which they reach Δ[DA] = 0 μM): in fast domains the x-
intercepts are all less than 0.5 s, while in slow domains they are all more than 1.2 s.  The x-
intercept times are significantly shorter in the fast domains compared to slow domains (Fig 4.3D: 
see the figure legend for ANOVA details).  Fig 4.3 confirms that apparent DA clearance is 
domain-dependent. 
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Figure 4.3 Fast and slow striatal domains exhibit significantly different rates of DA clearance.  
(A and B)  Normalized clearance profiles exhibit significantly different apparent DA clearance rates (n=4, One-way 
ANOVA, F(1,6)=28.38, † p=0.0018).  (C) Individual regression lines for the data set used to construct figure (4.2C) 
demonstrate that the distinction in apparent DA clearance rates is independent of the initial amplitude.  The 
categorization of a response as fast-type or slow-type is not based on the amplitude of the evoked response but rather 
its temporal profile, as explained by Fig 4.1.  Thus, fast-type and slow-type evoked responses often have similar 
amplitudes (Fig 4.1B, 4.2A).  Even when the amplitudes are similar, the distinction in apparent clearance rate is 
maintained.  (D) The fast-type regression lines intersect the x-axis significantly faster than the slow-type regression 
lines independent of initial evoked amplitude (n=4, One-way ANOVA – Tukey post-hoc, F(1,6)=64.17, † p=0.0002). 
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4.5 DISCUSSION 
 
The present study extends our on-going efforts to characterize the fast and slow domains of the 
striatal DA terminal field.  It is well-known that the striatum is heterogeneous with respect to DA 
(May and Wightman 1989b; Kawagoe et al 1992; Garris and Wightman 1995; Wightman et al 
2007).  However, the compartmentalization of DA terminals into distinctive domains is a 
relatively recent concept (Moquin and Michael 2009; Wang et al 2010).  Our prior studies 
demonstrated that the domains are distinguished by the autoinhibition-dependent dynamics of 
evoked DA release.  The autoinhibition of evoked DA release (Fig 4.1), an accepted index of 
vesicular release, suggests that DA reaches the extracellular space of slow domains via a non-
vesicular mechanism.  So, the domains apparently exhibit different basal DA concentrations as a 
consequence of different rates and mechanisms of DA release.  Much as we would like to, thus 
far we have not been able to examine this implication by directly measuring basal DA 
concentrations in the two domains.  So, we have examined instead the related prediction that the 
domains should exhibit different apparent rates of DA clearance.   
 
4.5.1 Different basal DA concentrations in the two domains 
The raclopride-sensitivity of the initial delay in the onset of evoked DA release (Fig 4.1A) 
indicates that DA terminals within slow domains are tonically autoinhibited, while the 
raclopride-insensitivity of the fast-type evoked release (Fig 4.1C and 4.1D) indicates that the 
terminals are not tonically autoinhibition.  However, the fast domains exhibit autoreceptor 
function in the form of short-term depression of evoked release (Fig 4.1B) and sensitivity to 
quinpirole, a D2R agonist (Wang et al 2010).  Since autoreceptors are functional in both 
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domains, it appears that the domain difference in autoinhibitory tone derives from a difference in 
the basal DA concentration available to activate, or not, the D2Rs.  
 
4.5.2 Prospects for direct detection of basal DA in striatal domains 
Voltammetry measures extracellular DA with sufficient spatial and temporal resolution (May 
and Wightman 1989b; Kawagoe et al 1992; Garris et al 1994; Peters and Michael 2000; Greco 
and Garris 2003) to, for instance, expose the fast and slow striatal domains.  But, it is poorly 
suited to determining steady-state DA concentrations (e.g. Heien et al. 2005).  Although this 
limitation might eventually be resolved, voltammetry in its present form does not have the 
demonstrated ability to measure basal DA concentrations.  Microdialysis is widely adopted for 
basal measurements but does not have the necessary spatial resolution to selectively sample DA 
from one domain or the other.  So, the present study takes advantage of votlammetry’s ability to 
quantify DA clearance, which reflects the balance in the rates of DA uptake and release that is 
ultimately responsible for the extracellular DA concentration. 
The two striatal domains exhibit significant differences in both apparent clearance rate, 
deduced from the slope of the initial linear segments of the clearance profiles, and the 
extracellular DA lifetime (Fig 4.2 and 4.3).  The DAT is saturable, so a difference in the rate of 
clearance could arise if the DAT were saturated during some measurements but not others.  All 
the clearance profiles, however, exhibited an initial linear segment, which shows that clearance 
was zero-order in all cases, so the DAT was saturated in all cases.  Differences in clearance time 
could be due to differences in the initial amplitude, i.e. it might take longer to clear DA after 
large-amplitude evoked responses simply because there is more of it to clear.  This does not 
seem to be the main source of differences in lifetime: the lifetimes were clearly distinct in the 
two domains (Fig 4.2A), even though there was considerable overlap in the initial amplitude (Fig 
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4.3C and 4.3D).  Differences in the apparent rate of DA clearance could also arise from D2R 
activation (Cass and Gerhardt 1994; Dickinson et al 1999; Wu et al 2002). However, these 
studies demonstrate that D2R activation accelerates the apparent rate of DA clearance, which is 
not what we observed: we found slower clearance in the presence of tonic autoinhibition. 
Although DA clearance is known to be heterogeneous in the striatum (Garris et al 1993), this is 
the first study to show significant differences in DA clearance between sites associated with fast-
type and slow-type evoked responses. 
 
4.5.3 Defining the apparent rate of DA clearance 
The apparent rate of DA clearance is measured with voltammetry as the extracellular DA 
concentration returns to its basal level following a transient increase induced either by 
electrically evoking the release of endogenous DA (Wu et al 2001) or by ejecting exogenous DA 
into the extracellular space via a pipet (Cass et al 1993; Sabeti et al 2002).  The apparent rate of 
clearance is the net rate at which DA is delivered to, and removed from, the recording electrode 
(Chen 2005; Michael et al 2005).  Since clearance occurs after the electrical stimulus or 
pressure-ejection, the delivery process of interest is the spontaneous (i.e. non-evoked) release of 
endogenous DA.  DA removal occurs by uptake and diffusion (Wightman et al 1988; Venton et 
al 2002; John and Jones 2007).  However, the linearity of the initial segment of the clearance 
profiles (Fig 4.2C and 4.3A) indicates zero-order rate processes.  So we can conclude that 
diffusion, which is not a zero-order rate process (Hrabetova and Nicholson 2007), does not 
contribute substantially to the initial linear stage of clearance. 
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Thus, during the initial linear stage of clearance, the apparent rate of DA clearance, 𝑉𝑎𝑝𝑝𝑜 , 
is the difference between the rate of DA uptake, 𝑉𝑢𝑜, and the rate of DA release, 𝑉𝑟𝑜 (Michael et 
al 2005):
   
Equation 2: 
VVV ruapp 000 −=
 
where the superscripts “o” indicate zero-order rates.  In some cases, 𝑉𝑢𝑜 might correspond to the Vmax of uptake from the Michaelis-Menton model (Wu et al 2001; Montague et al 2004; Kita et 
al 2007), i.e. the maximal possible rate of uptake when the extracellular concentration of DA is 
sufficient to saturate the DAT and all of the DAT protein is available to participate in uptake.  
But, if DDE occurs, then some of the DAT protein would not be available for uptake and the 
zero-order uptake rate would be less than Vmax.  To leave open this possibility, we have used 𝑉𝑢𝑜 
rather than Vmax to denote the intrinsic zero-order uptake rate in Equation 2. 
Equation 3 explains how basal DA concentrations depend upon the rates of release and uptake 
(Chen 2005; Michael et al 2005):  
Equation 3: 
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where C* represents the basal DA concentration, 𝐾𝑚 is the DAT’s Michaelis constant, and the 
other terms were defined earlier.  As explained above, we have replaced 𝑉𝑚𝑎𝑥with 𝑉𝑢𝑜 to leave 
open the possibility that some DAT proteins are not available for uptake. Since the denominator 
of Equation 3 is 𝑉𝑎𝑝𝑝𝑜 , it predicts an inverse relationship between 𝑉𝑎𝑝𝑝𝑜  and C*. 
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4.5.4 The inverse relationship between C* and 𝑽𝒂𝒑𝒑𝒐    
The absence of tonic autoinhibition in the fast domains might be due to a low basal DA 
concentration.  According to Equation 3, a low C* would derive from slow release (the 
numerator) and/or fast apparent clearance (the denominator).  When release is slow, the apparent 
clearance rate should approach the maximal intrinsic rate, Vmax, i.e. 𝑉𝑎𝑝𝑝𝑜 ≈ 𝑉𝑢𝑜 and 𝑉𝑢𝑜 ≈ 𝑉𝑚𝑎𝑥.  
In a less-likely scenario, a low C* could derive from fast release if 𝑉𝑎𝑝𝑝𝑜  were correspondingly 
even faster (this scenario is unlikely because it implies a high expenditure of energy for no 
apparent reason).  In either case, rapid clearance implies a low concentration.  Therefore, fast DA 
clearance in fast domains supports the hypothesis that tonic autoinhibition is absent because the 
basal DA concentration is low, presumably too low to activate D2Rs. 
Tonic autoinhibition in slow domains might be due to a high basal DA concentration.  
According to Equation 3, a high C* would derive from fast release and/or slow apparent 
clearance.  When release is fast, apparent clearance should be slow, because 𝑉𝑎𝑝𝑝𝑜 = 𝑉𝑢𝑜 − 𝑉𝑟𝑜 
(Equation 2).  As explained above, basal release in slow domains is likely non-vesicular.  If this 
were to involve DDE, then 𝑉𝑢𝑜 ≪ 𝑉𝑚𝑎𝑥 and apparent clearance would be slowed further.  So, 
slow apparent clearance implies a high concentration, supporting the hypothesis that the 
autoinhibitory tone on DA terminals in slow domains is a consequence of a high basal DA 
concentration, presumably high enough to tonically activate D2Rs. 
 
4.5.5 Does DDE contribute to release in slow domains? 
Equation 3 allows the alternate scenario that a high C* could derive from slow release if 
clearance were correspondingly even slower (note, however, there must be some release or C* 
goes to zero).  Slow release and slow clearance might derive from a striatal location with a low 
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density of DA terminals.  In this scenario, again, the apparent clearance rate would approach the 
maximal intrinsic uptake rate, Vmax, i.e. 𝑉𝑎𝑝𝑝𝑜 ≈ 𝑉𝑢𝑜 and 𝑉𝑢𝑜 ≈ 𝑉𝑚𝑎𝑥, but 𝑉𝑚𝑎𝑥 would be small 
because there are few DATs.  This scenario, in which slow clearance still implies a high C*, 
upholds our hypothesis that the autoinhibitory tone is due to a high basal DA concentration. 
However, if there are so few DATs then DDE might not be possible and vesicular release, even 
though it is autoinhibited, would have to be sufficient to tonically activate D2Rs.  As discussed 
next, there are several reasons to think this scenario is unlikely.  
A low density of DA terminals is inconsistent with the large amplitude of evoked release 
once autoinhibition is alleviated with raclopride (Fig 4.1C and 4.1D).  The nomifensine-
sensitivity of the slow-type evoked responses (Fig 4.2E and 4.2F) shows that the slow domains 
contain DAT, which is expressed by DA terminals (Ciliax et al 1995; Nirenberg et al 1996).  Our 
finding that diffusion is not a major contributor to the initial segment of clearance (Fig 4.2C and 
4.2D implies the close proximity of DATs to the recording electrode.  The rapid onset of DA 
clearance when the stimulus ends also indicates the presence of functional DATs near the 
electrode (Moquin and Michael 2009).  Moquin and Michael (2009) thoroughly established that 
the slow-type responses exhibit multiple features that cannot be explained by diffusion. 
Equation 3 shows that a domain difference in basal DA concentration requires a 
difference in the relative rates of release and uptake.  Apparent clearance is approximately 5-fold 
slower in slow domains compared to fast (Fig 4.2C).  Meanwhile, Moquin and Michael (2009: 
Figure 2.5C) found that raclopride increases the rate of slow-type evoked release approximately 
5-fold, suggesting that autoinhibition slows vesicular release approximately 5-fold.  Thus, the 
relative rates of clearance and vesicular release are not sufficiently different to produce different 
basal concentrations.  So, we conclude that autoinhibited vesicular release is insufficient to drive 
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an increase in basal DA concentrations, which supports the hypothesis that a non-vesicular 
process is responsible for the autoinhibitory tone.  
Ancillary observations further support a role for DDE.  For example, raclopride promoted 
slow-domain evoked release when administered directly to the striatum (Fig 4.1C and 4.1D), 
which confirms that the low amplitude of slow-type evoked release stems from presynaptic 
events rather than a low-density of terminals.  Furthermore, Borland and Michael (2004) 
reported a tetrodotoxin-insensitive, nomifensine-sensitive pool of extracellular DA in the 
striatum, while Wang et al (2010) found that this pool correlates with the domain type. 
Collectively, these various findings confirm that the type of domain is determined by the rate and 
mechanism of the processes that control the basal DA concentration, rather than the local density 
of DA terminals.  
 
4.5.6 Clearance after evoked release and pressure-ejection  
Several studies have discussed why DA clearance after pressure-ejection appears to be slower 
than after evoked release (Cass et al 1993; Cass and Gerhardt 1994; Kiyatkin et al 2000; Sabeti 
et al 2002).  For example, since the DAT is electrogenic, there is a concern that the membrane 
depolarization associated with the use of electrical stimulation might bias the DAT kinetics.  
However, we obtained close agreement between clearance after evoked release and pressure-
ejection (Fig 4.2E) by establishing several experimental conditions.  First, clearance after evoked 
release and ejection were measured at the same recording site.  Second, the initial amplitude of 
the clearance profiles after ejection and evoked release were made similar by placing the ejection 
pipet immediately adjacent to the recording microelectrode (Fig 3.1) and by adjusting the 
ejection time.  Third, by placing the ejection pipet adjacent to the microelectrode, we kept the 
ejection time brief so that the ejection was finished prior to the clearance measurement.  Fourth, 
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we performed the measurements in slow domains.  Under these conditions, clearance after 
evoked release and pressure-ejection was indistinguishable (Fig 4.2E): this corroborates the slow 
apparent clearance rate and confirms that no bias was introduced by the use of a longer stimulus 
to overcome the autoinhibition of evoked release in the slow domains.   
Thus, it appears that the domains may have contributed to the discrepancy between DA 
clearance rates after evoked release and pressure-ejection noted in prior studies.  Voltammetry 
protocols usually involve a procedure to optimize the placement of the recording electrode.  As 
we have shown, optimization seeks out those domains where DA clearance is inherently fast.  
The pressure-ejection technique does not seek out the fast domains and so likely reflect slow-
domain clearance.  
We have not, however, attempted to evaluate DA clearance after pressure-ejection into fast 
domains.  Thus far, we have not been able to identify purely fast recording sites: rather the 
electrodes straddle fast and slow domains, giving rise to hybrid responses.  We assume that 
pressure ejection would not permit the delivery of exogenous DA only into the fast subdomain of 
a hybrid site.  However, we do not expect the electrogenic properties of the DAT to be a key 
factor in the faster DA clearance because we only stimulated the fast sites for 200 ms: thus, we 
evoked far less depolarization in the fast sites and, presumably, far less disruption of ion 
activities.  
 
4.6 CONCLUSION 
 
Figure 4.4 schematically summarizes the DAergic function of the fast and slow striatal domains 
that emerges from these studies.  The fast domains operate under the control of an avid uptake 
process that rapidly clears DA from the extracellular space and maintains a low basal DA 
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concentration.  The DAT primarily engages in uptake, so DDE is negligible and DA release is 
dominated by the vesicular mechanism.  This is the conventional view of DAergic function 
deduced from voltammetric studies wherein the placement of the recording electrode was 
optimized to find fast-type DA.  The fast-type responses reported here are similar to the 
optimized responses reported by other investigators.  For example, the DA clearance rate we 
report in fast domains is similar to conventional values (Wu et al 2001; Venton et al 2003) and 
prior studies have demonstrated that short-stimulus responses at optimized recording locations 
are refractory to D2R antagonists (Garris et al 1994).  On the other hand, DA clearance is 5-fold 
less-avid in the slow domains and this coincides with a higher basal DA concentration to 
tonically autoinhibit vesicular release.  Autoinhibited vesicular release is insufficient to increase 
the extracellular DA concentration in the slow domains (Equation 3), so it appears that non-
vesicular release contributes to the basal DA tone.  This supports the conclusion that the DAT, 
even though it is conventionally viewed as a DA reuptake site, contributes to functionally 
relevant DA release. 
There are indications that tonic firing of midbrain DA neurons drives tonal vesicular DA 
release (Floresco et al 2003; Venton et al 2003), but presumably this is only relevant in the fast 
domains where vesicular release is not autoinhibited.  The slow domains, wherein DA release is 
dominated by non-vesicular processes, appear to operate along-side the fast domains.  The 
physiological implications of the domain architecture remain to be fully elucidated but are a 
matter of on-going interest. 
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Figure 4.4 The interaction of DAT, basal DA, D2R mediated autoinhibition, and evoked DA release in fast 
and slow domains.  
(A) In fast domains, the DAT favors DA uptake, leading to rapid evoked DA clearance. This rapid DA clearance 
maintains a basal DA concentration below D2R activation. Thus, tonic autoinhibition is off, enabling terminals to 
release DA immediately upon stimulation. (B) In slow domains the DAT favors DA efflux, leading to slowed 
evoked DA clearance. Constant DDE maintains a basal DA concentration large enough to activate D2Rs. Tonic 
D2R activation creates a constant autoinhibitory tone on these terminals, preventing evoked DA release at the onset 
of stimulation. 
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5.0 CONCLUSIONS 
 
This dissertation concludes that the striatal DA system is comprised of two domains of neuron 
terminal function; the fast domain, which fits the classic model, and the previously unidentified 
slow domain. Further, we reveal that the slow domain is a product of DAT mediated DA efflux. 
Constant efflux elevates the basal DA concentration above D2R binding, causing tonic 
autoinhibition of evoked release. The discovery of slow-type terminal function has the potential 
to revolutionize our understanding DA signaling. However, there are many more questions that 
must be answered in order to fully characterize slow domains and their role in the nigrostriatal 
pathway.   
For example, it is still unclear what drives different DAT function in fast and slow 
domains. One possibility is that anatomical differences in either the expression of DAT at the 
terminal surface or the density of DA terminals plays a role in setting the basal DA 
concentration. In order to address these possibilities we are currently probing the anatomy of fast 
and slow domain tissue using scanning electron microscopy. Also, intracellular processes could 
contribute to differences in DAT function. For example, the cytosolic DA concentration could 
drive the rate of DA efflux. In this proposed model, when the cytosolic DA concentration is low 
efflux is minimal and DAT’s main function is uptake. Elevated cytosolic DA concentrations 
increase the rate of DA efflux, driving DA release via DAT.   
Second, we must examine the effects of DA drugs in slow domains. Drug effects on the 
basal DA concentration and phasic DA release in fast domains has lead to a wealth of 
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information on terminal function (Cass and Gerhardt 1994; Garris and Wightman 1995; Sonders 
et al 1997; Dickinson et al 1999; Benoit-Marand et al 2001; Robinson et al 2001; Rougé-Pont et 
al 2002; Wightman and Robinson 2002; Garris et al 2003). However, the disparate effects of 
raclopride on evoked release (Moquin and Michael 2009)  and kynurenate on basal DA (Wang et 
al 2010) in fast and slow domains clearly indicate that drugs can have different effects in each 
domain. Therefore, it is paramount to categorize drug effects in slow domains in order to 
understand slow domain terminal function and it’s relation to fast domain activity.  
For example, early reports on the effect of DAT inhibitors in slow domains shows that 
the DAT inhibitor, nomifensine, similarly to raclopride, converts slow-type evoked responses to 
fast-type (Young and Michael 1993). Thus, DAT inhibition appears to terminate autoinhibition 
in slow domains, which might indicates that DAT inhibition also inhibits DA efflux.  This raises 
the possibility that the mechanism of action of drugs that inhibit the DAT might be distinct in 
fast and slow domains, which has interesting implications for the understanding of both the illicit 
and medicinal applications of such compounds.  
Finally, it is necessary to understand how slow domains regulate post-synaptic GABA 
cell activity. While this dissertation focuses only on pre-synaptic terminals, the DA neuron’s 
main role in the striatum is to interact with the GABA cell. Our data has shown that terminals in 
slow domains are under tonic autoinhibition of evoked DA release derived from pre-synaptic 
D2R activation. The post-synptic GABA cell expresses both D1 and D2 receptors. D1 and D2 
receptors have similar binding coefficients, so it stands to reason that post-synaptic receptors are 
continuously activated in slow domains (Grigoriadis and Seeman 1985). Thus, we hypothesize 
that post-synaptic GABA cells are under a constant DAergic tone in slow domains, i.e. constant 
DA signaling. The existence of distinct fast and slow DA domains accords well with the concept 
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that DA functions on multiple time courses (Schultz 2007). Further, the slow domain adds new 
insights into several DA pathologies.   
In Parkinson’s disease there is a near complete neurodegeneration of the striatal DA 
system. The loss of striatal DA activation of GABA cells leads to enhanced activity of the basal 
ganglia, which is thought to cause the loss of motor control (Albin et al 1989; Maneuf et al 
1997). However, there is a significant pre-symptomatic phase where the striatal DA terminals are 
significantly decreased without outward signs of the disease (Bernheimer et al 1973; Robinson 
and Whishaw 1988).  Zigmond and co-workers have hypothesized that increased DA production 
and release by surviving DAergic terminals compensates for the decline of the DAergic system 
during the pre-symptomatic phase of Parkinson’s disease (Zigmond et al 1992). They further 
hypothesize that DA would have a longer lifetime in the extracellular space because uptake is 
significantly slower due to the decreased number of uptake sites (Zigmond et al 1992).  
Therefore, they suggest that the remaining DAergic terminals are able to create a long lasting 
tonic DA signal that helps maintain homeostasis in the denervated striatum (Zigmond et al 
1992). The current pharmaceutical treatments of Parkinson’s disease, D2R agonists (e.g. 
quinpirole) or L-DOPA, also appear to alleviate Parkinson’s disease symptoms through tonic 
activation of receptors. Administration of quinpirole alleviates akinesia the Parkinson’s disease 
rat model by activating D2Rs (Maneuf et al 1997). There is no evidence that quinpirole can be 
packaged and released by neurons, and thus assume that it acts tonically on the receptors.  
Similarlly L-DOPA, which is converted into DA by aromatic L-amino acid decarboxylace, a 
ubiquitous enzyme that decarboxylizes all natural aromatic L-amino acids (Lovenberg et al 
1962) increases striatal DA (Hefti et al 1981; Keller et al 1988). However, as the number of 
DAergic terminals has been greatly reduced it is believed that that much of the DA produced 
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from L-DOPA occurs in non-DAergic cells (Melamed et al 1980), and enters the extracellular 
space in a non-impulse dependent manner (Zigmond et al 1992). The notion that there is a 
homeostatic level of basal activation of post-synaptic DA receptors fits with our model of two 
striatal DA domains.  
Schizophrenia is highlighted by both positive (e.g. delusions) and negative (e.g. 
anhedonia) emotional responses. One hypothesis on the duality of schizophrenic symptoms 
suggests that the basal DA concentration exists in a homeostatic state. Either an increase or 
decrease in this basal level causes an imbalance in DA signaling, triggering either positive or 
negative schizophrenic activity (Grace 1991). This hypothesis does not fit with the classic model 
of striatal DA signaling. In the classic DA model, lowering basal concentrations from nM to zero 
would have no effect DA receptor binding (Grigoriadis and Seeman 1985), suggesting that only 
increases in DA trigger disorders. The large basal DA concentration found in the slow domain 
resolves this discrepancy. Here, decreasing the basal DA concentration would change DA 
receptor binding, altering DA signaling.  
In the classic ADHD model increased phasic DA signaling is the root cause of 
hyperactivity (Levy and Swanson 2001; Tripp and Wickens 2008). The symptoms of ADHD are 
successfully treated with methylphenidate, which elevates the basal DA concentration (Volkow 
et al 2001). The efficacy of methylphenidate is paradoxical in the classic model where increasing 
basal DA should only serve to further activate DA receptors. Slow domains provide a new 
hypothesis, resolving this issue. Slow domains have a large basal DA concentration that triggers 
tonic autoinhibition. These terminals do not release DA during physiologically relevant stimulus 
events (Moquin and Michael 2009). The effect of raclopride demonstrates that these terminals 
are capable of rapid DA release (Moquin and Michael 2009). So a decrease in basal DA in these 
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domains would remove the tonic autoinhibitory tone, turning slow domains into fast domains. 
An increase in the number of fast domains would increase phasic DA signaling. Therefore, 
ADHD may be caused by a decrease in the basal DA concentration that increases the ratio of fast 
domains compared to slow domains. In this model, methylphenidate increases basal DA 
converting fast domains back into slow domains, restoring the proper ratio of the two domains.  
 These revised models of DA pathologies highlight the significance of slow domains in 
the striatal DAergic pathway. Continued research into slow domain function will reveal new 
insights into DA signaling, enlightening our perspective on mammalian brain function, the 
causes of brain disorders, and potential cures.  
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